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Zika virus (ZIKV) is an emerging mosquito-borne flavivirus primarily transmitted by 
mosquitoes and ticks. Recent ZIKV outbreaks have produced serious human disease, 
including neurodevelopmental malformations and Guillain-Barré syndrome. These 
outcomes were not associated with ZIKV infection prior to 2013, raising the possibility 
that viral genetic changes could contribute to new clinical manifestations.  
In my studies, I investigated the role of E protein glycosylation in ZIKV 
pathogenesis. I found that glycosylated viruses were highly pathogenic in Ifnar1-/- mice, 
whereas non-glycosylated viruses were attenuated, producing lower viral loads in the 
serum and brain when inoculated subcutaneously, but replicating equally well in the brain 
when inoculated intracranially. These results suggest that E glycosylation is 
advantageous in the periphery but not within the brain. Accordingly, I found that 
glycosylation facilitated infection of lectin expressing cells, possibly explaining the 
attenuation of non-glycosylated ZIKV in mice. Additionally, I found that adding a glycan 
back to the E protein at a different position (N67) does not functionally complement the 
loss of the glycan at position N154. 
I also discovered two strain-specific determinants of ZIKV virulence in mice. I found 
that H/PF/2013 caused 100% lethality in Ifnar1-/- mice, whereas PRVABC59 caused no 
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lethality. Deep sequencing revealed a high-frequency variant (V330L) in PRVABC59 not 
present in H/PF/2013. I showed that the V330 variant is lethal on both strains, whereas 
the L330 variant is attenuating only on the PRVABC59 background. To investigate the 
remaining differences between the two strains, I made a panel of chimeric viruses with 
nucleotide sequences derived from H/PF/2013 or PRVABC59. I found that 6 nucleotide 
differences in the 3’ quarter of the H/PF/2013 genome were sufficient to confer virulence 
in Ifnar1-/- mice.  
Altogether, I confirmed that the E protein glycosylation mediates pathogenesis of 
ZIKV from both Asian and African-lineage strains, and I identified a large and previously 
unreported difference in virulence between two commonly used ZIKV strains, in two 
widely used mouse models of ZIKV pathogenesis (Ifnar1-/- and Ifnar1-/- Ifngr1-/- DKO 
mice). My studies emphasize how small genetic changes in viruses can lead to drastically 
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The Flavivirus genus, in the family Flaviviridae, includes human pathogens, such 
as West Nile virus (WNV), Japanese encephalitis virus (JEV), dengue virus (DENV), 
yellow fever virus (YFV), tick-borne encephalitis virus (TBEV), and Zika virus (ZIKV). Most 
flaviviruses are vector-borne, transmitted by mosquitoes and ticks. Many of these 
arboviruses are capable of causing severe diseases, such as encephalitis, hemorrhagic 
fever, and birth defects (1, 2). Thus, the endemic transmission of flaviviruses in certain 
regions of the world, as well as their emergence in new areas, represents a significant 
public health burden as well as a threat to livestock and wildlife(3–6).  
1.2 Flavivirus genome organization and replication 
 
 Flaviviruses are enveloped, positive-sense single-stranded RNA viruses. The 
flavivirus genome is translated as a single open reading frame flanked by 5’ and 3’ 
untranslated regions (UTR) (7). The polyprotein is proteolytically cleaved co- and post-
translationally by host and viral proteases into three structural proteins, capsid (C), 
premembrane/membrane (prM/M), and envelope (E), as well as seven non-structural 
proteins (NS1, NS2A, NS2B, NS3, NS4A NS4B, and NS5) (8–10).  
_____________________ 




Both prM and E are incorporated into the viral envelope in a highly ordered conformation. 
prM participates in the proper folding, maturation, and assembly of E during replication 
(9, 11). E facilitates membrane fusion between the virus and host cell, and is the primary 
viral protein against which neutralizing antibodies are produced (9, 12, 13). Flavivirus E 
proteins form head-to-tail homodimers, 90 of which assemble to form a virion surface with 
2-fold, 3-fold, and 5-fold symmetry axes (14). Flavivirus E proteins are class-II fusion 
proteins with three distinct domains: domain I (EDI), domain II (EDII), and domain III 
(EDIII) (Fig 1.1A) (10, 15–19). EDI and EDII are discontinuous, forming a central β-barrel 
and elongated dimerization region, respectively, while EDIII forms a continuous C-
terminal, immunoglobulin-like domain (15). There is ~40% amino acid identity among the 
flavivirus E proteins. After virion attachment to the cell and endocytosis, flexible hinges 
that connect the three E domains enable irreversible conformational changes during pH-
dependent membrane fusion inside the endosome (10, 13, 15, 19). Flavivirus replication 
and assembly occurs on endoplasmic reticulum (ER) membranes, with encapsidated 
genomes acquiring their envelope as they bud into the ER lumen. The pr peptide is 
positioned at the distal end of EDII within the heterodimer where it obscures the fusion 
loop on E proteins of immature virions (20). Transit of assembled virions through the 
acidic compartments of the trans-Golgi network results in a reorganization of the surface 
of the virus particle. This pH-dependent change in virion structure exposes a cleavage 
site on prM and the pr portion is cleaved by host furin-like proteases in the Golgi to form 
mature, infectious particles (9, 10, 21, 22).  
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1.3 Zika virus 
 ZIKV is a mosquito-borne flavivirus, closely related to DENV, whose natural 
transmission cycle circulates between vectors from the Aedes genus and mammalian 
hosts (23). ZIKV was first isolated in 1947 from the blood of a sentinel rhesus monkey in 
the Zika forest near Entebbe, Uganda (24). Over the next sixty years, serological and 
entomological data revealed small sporadic outbreaks in Africa and southeast Asia (25–
29). In 2007 the first ZIKV outbreak outside of Africa and Asia was reported on Yap 
Island, Federated States of Micronesia (30). Symptomatic patients showed signs of 
fever, rash, conjunctivitis, arthralgia, and arthritis, termed Zika fever. Serological 
estimates suggest that more than 70% of the population had been exposed to ZIKV 
(30). This outbreak highlighted the potential of ZIKV to spread to new locations and 
cause illness in humans. Subsequently, ZIKV spread from Southeast Asia, across the 
Pacific Ocean, and into the Americas, with outbreaks in Cambodia in 2010 (31), in 
French Polynesia in 2013-2014 (32), and most notably in Brazil in 2015 (33). The 
spread of ZIKV to the Western Hemisphere also was accompanied by unexpected 
clinical manifestations that had not been associated with ZIKV prior to 2013. The 2013-
2014 ZIKV outbreak in French Polynesia was associated with an increase in Guillain-
Barré syndrome, an autoimmune neuropathy that can result in weakness, paralysis, and 
death (2, 34, 35), while the outbreak in Brazil and the rapid spread of ZIKV to many 
countries in the Americas (33, 36–38) has revealed that ZIKV infection during 
pregnancy can cause a broad range of congenital malformations termed congenital Zika 
syndrome (2, 39, 40). It is unknown why such severe disease manifestations were only 
revealed during the most recent ZIKV outbreak, but one explanation could be viral 
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genetic changes. Phylogenetic analyses have grouped ZIKV into two major lineages: 
African and Asian, with strains that emerged in the Pacific Islands and Latin America 
belonging to the Asian lineage (41). Analysis of the viral genetic changes that have 
evolved over time is vital to fill major gaps in our knowledge regarding ZIKV genetic 
determinants of pathogenesis.  
1.4 Flavivirus envelope protein glycosylation 
 
 Many flaviviruses contain an N-linked glycosylation site (N-X-S/T) at amino acid 
N154 of E, where a glycan is added to the amide nitrogen of the asparagine (Asn, N) 
residue as the emerging protein is being translated (42). However, the number and 
position of predicted glycosylation sites are not conserved among all flaviviruses, nor 
among different strains of the same virus (43–47) (Fig. 1.1 B-C). For instance, most WNV 
strains (such as NY99) are glycosylated at N154, but some strains, such as Kunjin, are 
not (48). Similarly, all Asian lineage ZIKV strains, such as H/PF/2013 and PRVABC59, 
are glycosylated at N154, whereas some of the African lineage ZIKV strains are not (29, 
49). The prototype ZIKV strain includes both glycosylated and non-glycosylated variants, 
all designated “MR766”, which can be a source of confusion in the literature (50–52). 
DENV is unique among flaviviruses in that its E protein contains two N-linked 
glycosylation sites, one at N67 and a second at N153, which are present in most strains 
of the four DENV serotypes (8, 47, 53). E glycosylation plays important roles in viral 
attachment and cell entry, replication, transmission, and pathogenesis. The effects of 
glycosylation are particularly important for these vector-borne viruses because the 




1.5 Protein glycosylation in mammalian and insect cells 
 
 In mammalian cells, glycosylation takes place in the ER-Golgi complex where a 
network of glycotransferases and glycosidases enzymatically synthesize a diverse array 
of glycan structures (42, 54, 55). Briefly, a lipid-linked oligosaccharide, synthesized from 
the lipid dolichol, serves as a carrier of the glycan. Dol-PP-GlcNAc2Man5 is enzymatically 
synthesized on the cytoplasmic side of the ER membrane and then translocated across 
the membrane into the ER lumen where further monosaccharides are added. The final 
glycan structure is transferred co-translationally to the Asn residue of an appropriate N-
X-S/T motif via an oligosaccharyltransferase. Further processing takes place in the ER-
Golgi complex, where glycosidases trim the mannose residues before glycotransferases 
extend the “antennae” of the glycans to produce larger hybrid or complex structures. 
Many flaviviruses have avian amplifying hosts (e.g. WNV, JEV). Although glycosylation 
processes in avian cells have not been described as extensively as mammalian cells, 
bird-derived viruses likely have similar glycan structures as mammalian-derived viruses, 
as influenza viruses derived from chicken eggs, human embryonic lung fibroblast, or 
Madin-Darby canine kidney cells contain similar glycan structures, though at different 
frequencies (56, 57).  
 Protein glycosylation in insect cells has been best studied in organisms such as 
mosquitoes, fruit flies, and moths (58, 59). Ticks are another important arthropod vector 
of flaviviruses, but glycosylation pathways in tick cells have not been extensively 
described. The N-linked glycosylation pathway in insects begins like the mammalian 
pathway, with the synthesis and transfer of an oligosaccharide precursor, Dol-PP-
GlcNAc2Man9, to an appropriate Asn on a newly synthesized polypeptide (59). Studies of 
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N-linked glycosylation in mosquito cells suggest carbohydrate structures are not further 
processed to generate complex carbohydrates, but instead remain high mannose or 
paucimannose (3-mannose-residue) oligosaccharides (60–62). Because flaviviruses 
typically cycle between vertebrate and arthropod hosts, distinct glycan structures added 
by these host cells contribute to different properties of the viruses initiating each round of 
infection, as arthropod-derived virions with simple sugars initiate infection in vertebrate 
hosts, and vertebrate-derived virions with complex sugars initiate infection in arthropod 
vectors. This is important because the structure of the carbohydrate can have an impact 
on its function, such as binding to cell surface attachment factors and initiating infection 
(63). 
1.6 Envelope protein glycosylation and attachment 
 
 The first step in viral entry is virion binding to the cell surface. Cell surface molecules 
that facilitate virus binding and infection, but do not trigger fusion of viral and cellular 
membranes, are referred to as attachment factors (19). One family of attachment factors 
are lectins, proteins that bind carbohydrates, many in a calcium dependent manner (C-
type lectins) (19, 64). Two extensively studied C-type lectins are dendritic cell-specific 
intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN or CD209) and its 
paralog DC-SIGN-related protein (DC-SIGNR, L-SIGN, or CD209L). DC-SIGN is highly 
expressed in macrophages and dendritic cells (DCs), while DC-SIGNR is expressed on 
microvascular endothelial cells, especially in the liver sinusoids, lymph nodes, and 
placental villi (64). DC-SIGN and DC-SIGNR have been implicated in aiding the infection 
of numerous viruses such as human immunodeficiency virus (HIV), Ebola virus, Marburg 
virus, hepatitis C virus, human cytomegalovirus, Sindbis virus, and severe acute 
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respiratory syndrome coronavirus, as well as flaviviruses such as DENV and WNV (65–
75). 
 Glycosylated E protein interacts with cell surface lectins, facilitating attachment and 
infectivity (32, 33, 35-46). WNV strains containing E glycosylation at position N154 use 
DC-SIGN as an attachment factor, leading to enhanced infection compared to non-
glycosylated strains (67). DC-SIGNR has been shown to promote WNV infection much 
more efficiently than did DC-SIGN, particularly when the virus was grown in mammalian 
cells, and this was dependent upon E glycosylation at N154 (81). However, mutant WNV 
E proteins containing an N-linked glycosylation site at position N67 allowed WNV to 
interact with DC-SIGN (79). The DC-SIGN interactions were dependent on the 
incorporation of high mannose sugars at position N67, whereas DC-SIGNR recognized 
WNV bearing either complex or high mannose sugars (79). Likewise, JEV mutants 
containing glycosylation at position N67 showed enhanced DC-SIGN binding in HEK293T 
cells overexpressing DC-SIGN compared to viruses glycosylated at N154 (82). In contrast 
to the single glycan on most flavivirus E proteins, DENV is glycosylated at N67 and N153 
(8, 47, 53). A Cryo-EM study demonstrated that the carbohydrate recognition domain of 
DC-SIGN binds preferentially to glycans present at N67 on DENV particles (77). Hacker 
et al. showed all four DENV serotypes had N-linked glycans added to both N67 and N153 
of the E protein in both mammalian and mosquito cells, and viruses derived from both cell 
types were equally effective at infecting DC-SIGN expressing human monocytes and DCs 
(80). In DENV derived from mammalian cells, the N-linked glycans were a mix of high 
mannose sugars and complex sugars, while the N-linked glycans on mosquito-derived 
virus were a mix of high-mannose sugars and paucimannose sugars (80). Another study 
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revealed DENV lacking E glycosylation lost the ability to infect DC-SIGN and DC-SIGNR 
expressing cells (78). Altogether, these studies show that the location of the flavivirus E 
protein glycosylation motif, as well as the cell type the virus is propagated in, influence 
the final structure of the N-linked glycan, which in turn can influence virus binding to cell 
surface attachment factors and infectivity (Fig. 2). This is intriguing because E 
glycosylation also can impact the host antibody (Ab) response that is elicited to control 
the viral infection. A subset of highly potent, broadly neutralizing monoclonal Ab (MAb) to 
DENV (MAb 747(4)A11 and MAb 747(4)B7) were sensitive to glycosylation at N153 of 
DENV, showing lower activity against a naturally non-glycosylated DENV-4 strain 
compared to glycosylated strains (87). Conversely, studies of the arenavirus Lassa virus,  
showed envelope protein glycosylation acts as a shield, impairing the protective efficacy 
rather than the induction of neutralizing MAb, thereby preventing efficient antibody-
mediated virus control (88). This is similar to one of the best characterized glycan shields 
found on the HIV Env protein, with 18-33 glycans per gp120 monomer (89). The extent 
of these post-translational modifications, combined with the intrinsic flexibility of the 
trimeric Env and constant evolution of the glycan shield, renders HIV Env an 
immunologically challenging target (90–93). These data highlight the importance of 
understanding the biology of viral envelope protein glycosylation for vaccine development 
efforts against these pathogenic viruses. 
1.7 Envelope protein glycosylation and replication 
 
 E glycosylation plays a role in flavivirus attachment, however the roles of E 
glycosylation in flavivirus replication and assembly are less clear. Ablating N154 
glycosylation on TBEV resulted in impaired secretion of virus-like particles (VLPs) (94) as 
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well as altered conformation of secreted E protein and a corresponding decrease in 
infectivity (95). This effect was observed for E protein secreted from mammalian cells, but 
not tick cells, suggesting cell type-dependent effects of E glycosylation. Similarly, removal 
of the N-linked glycosylation site in E significantly reduced the release of WNV subviral 
particles (SVPs) but these non-glycosylated SVPs were more infectious than glycosylated 
SVPs, particularly on mosquito cells (96). Studies with ZIKV have shown glycosylation at 
N154 of the E protein significantly influenced expression, production, and secretion of the 
ZIKV E protein ectodomain as well as virus production and infectivity with VLPs (97). The 
reduction of virion or particle release may be due to impaired trafficking along the ER-
Golgi secretory pathway in the absence of appropriate E protein glycosylation. It also may 
be the consequence of incorrect E folding or interference with E dimerization, since 
glycosylation at N154 may stabilize the antiparallel E dimer conformation by keeping the 
fusion loop in place (18). However, ZIKV mutants lacking N154 glycosylation exhibit 
equivalent viral replication in mammalian and mosquito cells compared to glycosylated 
viruses (52, 98, 99). Nonetheless, these studies suggest flavivirus E glycosylation can 
influence viral particle assembly, secretion, and infectivity.  
 In addition to N154 glycosylation, DENV also contains a glycosylation site at N67 
of the E protein. Mondotte et al. found that E glycosylation was not essential for DENV 
replication in insect cells, although ablating the glycosylation at N67 (N67Q), but not N153 
(N153Q) resulted in a dramatic decrease of viral particle assembly or release in 
mammalian cells (83). Similarly, Bryant et al. observed that DENV E glycosylation at N67 
was important for growth in mammalian cells (100). However, though non-glycosylated 
(N67Q) virus was able to replicate in mosquito cells, a compensatory mutation arose 
10 
 
(K64N) introducing a new glycosylation site, suggesting glycosylation at N67 (or nearby 
N64) is selected in mosquito cells. Interestingly, non-glycosylated mutants replicated 
similarly in inoculated Aedes aegypti mosquitoes, with no change in their glycosylation 
status (100).   
 In contrast, Lee et al. found that N67 glycosylation was dispensable for efficient 
DENV release from mammalian cells, depending on the amino acid substitution 
introduced to abolish glycosylation (53). Ablating the glycosylation motif with a 
substitution of the Thr at position 69 of the N67 N-X-S/T motif, with a larger and more 
hydrophobic residue such as Val or Leu, retained efficient growth, whereas the 
introduction of an Ala residue at the same site reduced virus growth by >100-fold relative 
to the wild-type virus (53). Additionally, the conservative substitution of Asn to Gln at 
position 67 was markedly less detrimental for viral growth than the nonconservative 
change of Asn to Asp. Furthermore, Lee et al. found that a compensatory mutation 
(N124S) at a non-adjacent region in the E protein partially rescued the growth defect of 
the T69A mutant, without generating a novel glycosylation site (53). Moreover, they found 
strain origin of the E protein influenced the impact of ablating the glycan on viral growth 
(53). Ablating the E glycosylation at N67 of the DENV2 16681 strain prevented growth in 
mammalian cells, but was well tolerated in a chimeric virus encoding the prM and E 
proteins from strain PUO-218 which differs from 16681 at 4 residues. A region in DII, 
between residues 120 and 126, appears to play a role in overcoming the attenuated 
growth associated with ablation of the N67 glycan (53). These observations highlight that 
it can be challenging to define whether the glycan per se mediates infection, as opposed 
to the specific amino acid residues that comprise the glycosylation signal. For example, 
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different amino acid substitutions at E154/156 of WNV conferred distinct avian host and 
vector competence phenotypes independent of E-protein glycosylation status (101). 
Thus, in addition to the specific effects of E glycosylation, the underlying amino acids at 
E residues 67 and 154 also may affect viral attachment and infectivity. 
1.8 Envelope protein glycosylation and flavivirus transmission 
 
 Most flaviviruses are transmitted between hosts by arthropod vectors (mosquitoes 
or ticks), which acquire the virus during a blood meal (102). Vector-borne transmission 
requires the ingested virus to cross the midgut barrier and spread to the salivary glands 
to be transmitted to a new vertebrate host during a subsequent feeding (103, 104). 
Viruses must overcome multiple factors in the vector to be efficiently transmitted, 
including vector antiviral responses and tissue barriers (103, 104).  
 E protein glycosylation plays a role in flavivirus transmission via several 
mechanisms. Moudy et al. showed that non-glycosylated WNV replicated less efficiently 
than glycosylated WNV in Culex mosquitoes and was transmitted less efficiently (105). 
Interestingly, they found nearly all of the mosquitoes infected with non-glycosylated WNV 
transmitted a revertant virus, suggesting a strong selective pressure favoring glycosylated 
WNV in mosquitoes (105). E protein glycosylation could facilitate viral transmission 
across vector barriers by several mechanisms. Soluble carbohydrate-binding proteins 
could form a link between the virus and midgut surfaces or cell surface lectins could 
facilitate attachment to mosquito cells (106). In addition to facilitating transmission 
through attachment, the E glycan may also play a role in evading vector antiviral 
responses. Wen et al. found that ZIKV E N154 glycosylation promoted midgut invasion 
by inhibiting the reactive oxygen species (ROS) antiviral response (107). They further 
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showed that ablating E glycosylation (T156I), prevented mosquito infection via the oral 
route, whereas there was no effect on infection by intrathoracic injection, which bypasses 
the midgut.  
 Fontes-Grafias, et al. similarly showed that non-glycosylated ZIKV was very 
inefficient at infecting Ae. aegypti mosquitoes via a blood meal (99). However, in contrast 
to the ability of E glycosylation to facilitate attachment to mammalian cells, they showed 
that ZIKV with non-glycosylated E (N154Q), resulted in increased viral attachment, virion 
assembly, and infectivity of progeny virus in C6/36 mosquito cells compared to 
glycosylated virus (99). Another study showed ablating E glycosylation of DENV also 
increased virus entry but reduced virion release in C6/36 cells (53). These studies 
suggest the absence of E glycosylation is beneficial for infecting C6/36 cells in culture, 
but seems to be detrimental to the virus in mosquitoes. Thus, E protein glycosylation can 
aid flavivirus transmission by subverting tissue barriers and immunity-related pathways in 
arthropod vectors. 
 Though flaviviruses primarily are transmitted by arthropod vectors, vector-
independent transmission has been documented in a variety of circumstances including 
TBEV in unpasteurized milk, JEV among pigs, and WNV, Bagaza virus, and Tembusu 
virus among birds (108–113). An S156P mutation that ablated E glycosylation in 
Tembusu virus resulted in impaired transmission among ducks, suggesting that E 
glycosylation could facilitate vector-independent as well as vector-borne transmission of 




1.9 Envelope protein glycosylation and pathogenesis 
 
 Since E glycosylation can play a role in flavivirus attachment, replication, and 
transmission, it is not surprising that it also contributes to pathogenesis for some 
flaviviruses. Several studies have suggested a role for E protein glycosylation as a 
molecular determinant of neurovirulence. The 1999 emergence of WNV in the United 
States was characterized by large-scale mortality in wild birds, a phenomenon that had 
not been observed in earlier WNV outbreaks, as well as many cases of encephalitis in 
humans (115). In studies comparing WNV strains from the 1999 outbreak to historical 
WNV strains, E glycosylation was associated with increased brain infection and lethality 
in mice (116). Beasley et al. confirmed these findings by generating infectious clones of 
glycosylated virulent (NY99), and non-glycosylated attenuated (ETH76a) WNV strains 
and measuring their lethality in mice (117). They swapped the prM-E sequences of 
ETH76a into the NY99 infectious clone, or mutated residue N154 to abolish glycosylation 
in NY99, both of which resulted in attenuation of the virus to a level comparable to wild-
type ETH76a. Furthermore, a mutation that added the glycosylation to the ETH76a E 
protein on the NY99 backbone yielded a virus with virulence equivalent to wild-type NY99, 
indicating E protein glycosylation mediated the observed differences in virulence.   
 Other groups have generated chimeras of attenuated and highly virulent 
flaviviruses to analyze the role of viral E proteins in neuroinvasiveness (the ability of the 
virus to spread into the central nervous system from peripheral tissues) and 
neurovirulence (the ability of the virus to cause disease within the nervous system). Prow 
et al. generated a panel of Murray Valley encephalitis virus (MVEV) and Alfuy virus 
(ALFV) E protein mutants (118). MVEV causes encephalitis in humans, and isolates from 
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clinical material or mosquitoes are highly neuroinvasive in weanling mice (119, 120). In 
contrast, ALFV, a subtype of MVEV, has not been associated with human disease, and 
isolates are poorly neuroinvasive in weanling mice (121, 122). Their results showed that 
motifs within the E protein, including the absence of glycosylation and unique 
substitutions in the flexible hinge region, contribute to the reduced neuroinvasiveness of 
ALFV compared to MVEV (118).  
 However, multiple groups have generated chimeric viruses of neuroinvasive and 
non-neuroinvasive flaviviruses, and were unable to restore the neuroinvasive phenotype. 
A chimeric DENV4, containing the E glycoproteins of TBEV, was not neuroinvasive in 
adult BALB/c mice (123). Likewise, chimeric viruses consisting of the DENV4 backbone 
and the prM-E genes of Langat virus (LGTV) were not neuroinvasive (124). Chimeric 
WNV/DENV4 virus, in which the prM-E of WNV were put on the DENV4 backbone, lost 
the neuroinvasive properties of WNV (125), and replacing the prM-E of YFV, which is 
non-neuroinvasive, with prM-E of the neuroinvasive JEV, did not result in a virus that was 
neuroinvasive (126). These data suggest that prM and E of neuroinvasive flaviviruses are 
not sufficient to confer neuroinvasiveness to non-neuroinvasive flaviviruses.  
 To address the role of JEV E protein glycosylation in pathogenesis, especially the 
location and number of N-linked glycosylation on E proteins, Liang et al. generated three 
JEV mutants: one with glycosylation at N67, one with glycosylation at N67 plus N154, 
and one with no glycosylation on the E protein (N154A) (82). They found reduced viral 
growth in cell culture, as well as reduced neurovirulence and neuroinvasiveness in mice 
infected with the non-glycosylated or N67-only glycosylated virus compared to the wild-
type JEV with glycosylation at only N154 (82). The virus with both N67 and N154 E 
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glycosylation exhibited efficient replication in culture and neurovirulence in mice, but 
reduced neuroinvasiveness compared to the wild-type virus (82). The authors proposed 
that neurotropic flaviviruses with a single E protein glycosylation at N154 might have an 
enhanced ability to cross the blood-brain barrier, though the mechanism by which this 
would occur is unclear. Notably, the non-neuroinvasive flaviviruses DENV and YFV have 
two or zero E glycosylation sites, respectively. 
 Several recent studies with ZIKV have investigated whether N154 glycosylation 
contributes to neuroinvasion. After the large ZIKV outbreak in 2015 in Latin America, and 
the unexpected clinical manifestations associated with the outbreak, including 
neurodevelopmental malformations (congenital Zika syndrome) and Guillain-Barré 
syndrome (2), many studies have sought to identify the causative determinants of new 
disease phenotypes. All contemporary ZIKV isolates encode an N-linked glycosylation 
site in the E protein at position N154 but this glycosylation site is absent in many historical 
ZIKV isolates (29, 127, 128). Non-glycosylated (N154A) ZIKV mutants generated on the 
prototype strain MR766 background were attenuated in Ifnar1-/-  mice inoculated via a 
subcutaneous route, replicating to lower levels in serum and brain and causing less 
lethality compared to glycosylated virus (52, 98). Similarly, non-glycosylated (N154Q) 
mutants generated from Asian-lineage ZIKV strain FSS13025 also produced lower viral 
loads in the serum and brain compared to glycosylated virus, and were not virulent via a 
subcutaneous inoculation route (99).  
 Many of these studies identify a potential role for E glycosylation in flavivirus 
neurovirulence and pathogenesis. However, several studies conclude that the E 
glycosylation is a neuroinvasive determinant, implying that E glycosylation facilitates 
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trafficking across the blood-brain barrier. Studies with WNV and chimeric viruses made 
this conclusion based on the difference in lethality between peripheral inoculation routes 
(subcutaneous, intraperitoneal, or intravenous) and intracranial inoculations, observing 
that mice succumb to non-glycosylated viruses via intracranial but not peripheral routes. 
However, many of those studies did not measure viral loads in the serum of mice infected 
peripherally, and those that did found lower viral loads in mice infected with non-
glycosylated viruses. Such findings are similar to the results of more recent studies with 
ZIKV, in which non-glycosylated viruses are attenuated in the periphery, which likely 
contributes to lower viral loads in the brains, regardless of any effect of E glycosylation 
on neuroinvasion. Thus, whether E glycosylation truly mediates neuroinvasion (and the 
mechanism by which it might do so) remains an open question. 
1.10 Flavivirus strain variation and pathogenesis 
 
 Different strains of the same virus can have differential pathogenic outcomes in 
humans or animal models. For instance, WNV NY99 is lethal in mice, whereas WNV 
ETH76a and most WNV KUNV strains are not (117, 129). Similarly, MVEV is lethal in 
mice and pathogenic in humans, while ALFV, a subtype of MVEV, is attenuated (119–
122).  Different ZIKV strains also have varying degrees of virulence. ZIKV is grouped 
into two major phylogenetic lineages, African and Asian (29, 41). African lineage strains 
have been shown to be more virulent than some Asian strains and their pathogenicity is 
associated closely with the degree of inflammatory immune responses in mice (130). 
Interestingly, highly similar contemporary Asian strains, isolated during the recent 
outbreaks in the Western Hemisphere, have shown a wide range of pathogenic 
outcomes in different mouse models. ZIKV does not replicate efficiently in wild-type 
17 
 
C57BL/6 mice because ZIKV NS5 protein does not antagonize mouse STAT2 (131, 
132). Thus, various immunodeficient mouse models are used to study ZIKV 
pathogenesis, and the two most commonly used systems (Ifnar1-/- mice and Ifnar1-/- 
Ifngr1-/- DKO mice) largely have been assumed to yield comparable results. Ifnar1-/- 
mice lack the type I interferon-αβ (IFN-αβ) receptor, while Ifnar1-/- Ifngr1-/- DKO mice 
lack both the type I IFN-αβ receptor, as well as the type II IFN-γ receptor. Type I IFNs 
are essential for activating the antiviral innate immune response and are well known for 
their ability to directly induce an antiviral response within infected and surrounding cells 
through the upregulation of molecules that can antagonize virus replication (133). Type 
II IFN signals through a different receptor and has effects that are independent from 
type I IFN. As a part of the innate immune response, they are predominantly produced 
by natural killer cells during infection. Type II IFNs promotes antiviral immunity through 
its regulatory effects on the innate immune response and acts as a key link between the 
innate immune response and activation of the adaptive immune response (133). A ZIKV 
strain isolated in 2013 from French Polynesia (H/PF/2013) and a strain isolated in 2015 
from Brazil (Paraiba_01/2015) both have been shown to cause 100% and 80% lethality 
in Ifnar1-/- mice, respectively (134, 135). In contrast, a ZIKV strain isolated in 2010 from 
Cambodia (FSS13025) was only 20-30% lethal in Stat2-/- or Ifnar1-/- mice, and a strain 
isolated in 2015 from Puerto Rico (PRVABC59) was not lethal in either mouse model 
(136). However, the H/PF/2013, Paraiba_01/2015, FSS13025, and PRVABC59 strains 
were uniformly lethal in Ifnar1-/- Ifngr1-/- DKO mice (137–140). These data indicate ZIKV 
strain-specific contributions to virulence in mice, and highlight that differences in 
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pathogenesis may not be evident in highly susceptible models, such as Ifnar1-/- Ifngr1-/- 
DKO mice. 
1.11 Flavivirus RNA determinants of replication and pathogenesis 
 The Flavivirus open reading frame (ORF) is flanked by a 5’ UTR of about 100 
nucleotides (nt) and by a 3’ UTR of about 400 to 800 nt. The 3’ UTR contains large stem 
loop structures (SL). This secondary RNA structure is conserved among all flavivirus 
genomes and is essential for virus replication (141–143). A conserved sequence, 
located just 5’ of the 3’ terminal SL structure contains a highly conserved 8 nt sequence, 
called the 3’ cyclization sequence (3’ CYC). An exact complement of the 8 nt 3’ CYC 
sequence is located in the capsid coding region near the 5’ end of the genome. 
Genome cyclization due to the 3’–5’ long distance RNA–RNA interaction is required for 
the initiation of minus strand RNA synthesis but not for translation (141–143).  
Other RNA structures in the 3’ UTR result in the generation of small RNAs that 
impact flavivirus replication via multiple mechanisms. A key characteristic common to all 
arthropod-borne flavivirus infections tested to date is the generation and accumulation 
of a small 300–500-base subgenomic flavivirus RNA (sfRNA) (144). Flavivirus sfRNAs 
are generated by stalling of the cellular 5’–3’-exoribonuclease, Xrn1 in mammalian 
hosts and its homolog Pacman in insects, on the 3’UTR structures as it attempts to 
degrade viral positive-sense transcripts inside infected cells. The functions of sfRNA 
have been implicated in the induction of pathogenicity in mice and cytopathicity in cell 
culture, evasion of type I and type II IFN responses, decreased mRNA turnover, 
enhanced virus replication in mammalian cells, and for the infection and subsequent 





 The Flavivirus genus contains numerous viruses that are capable of causing a wide 
array of pathologic phenotypes in humans and mouse models. Phylogenetic analyses 
have sought to identify viral determinants that correlate to pathogenesis. One highly 
studied flavivirus determinant of pathogenesis is the N-linked glycosylation site on the E 
protein. N-linked glycosylation is a common post-translational modification which has 
significant effects on protein conformation and function (42). It is a complex process that 
is highly host cell- specific (42). Not all flaviviruses possess an E glycosylation but for 
many flaviviruses E glycosylation impacts viral fitness, infectivity, replication, and 
virulence. The producing cell type, whether from arthropod versus vertebrate cells or 
specific cell types within a host, likely impacts the nature of the glycan added to flavivirus 
E proteins, but the ultimate effect of these distinct glycan structures on viral transmission, 
infection, and pathogenesis remains incompletely understood. It is unclear why DENV 
uniquely maintains two E glycosylation sites, or conversely how YFV maintains efficient 
transmission, infection, and virulence without E glycosylation. Understanding the impact 
of the viral E glycosylation on the host Ab response could improve the development of 
vaccines and diagnostics, particularly for DENV and ZIKV. Whether flavivirus E 
glycosylation is a bona fide neuroinvasive determinant or simply enhances viral 
replication in the periphery, resulting in higher infection levels in the brain, requires further 
investigation. It is also unclear why such highly similar ZIKV strains result in differential 
pathogenesis in different mouse models. Answers to these questions will further our 
knowledge of flavivirus replication and pathogenesis and potentially aid in combating 








Figure 1.1. Flavivirus E protein glycosylation sites. (A) Domain organization of 
DENV E; stars indicate the glycosylation sites at asparagine (N) residues 67 and 
154. Numbers indicate amino acid residues comprising E domain I (red); domain II 
(yellow), and domain III (blue). (B) Glycosylation at N154 is highly conserved among 
flaviviruses, whereas glycosylation at N67 is unique to DENV. Genebank accession 
numbers for each virus are indicated. (C) Glycosylation at N154 can differ among 




   
Figure 1.2. Glycan structure influences E binding to attachment factors. 
Flaviviruses with non-glycosylated E have minimal binding to the lectins DC-SIGN or 
DC-SIGNR, whereas glycosylation at N67 or N154 facilitate virus binding to cell-
surface lectins. Simple (high mannose) glycans are preferentially added at N67 and 
facilitate binding to DC-SIGN or DC-SIGNR expressing cells. In contrast, complex 







CHAPTER 2 – ENVELOPE PROTEIN GLYCOSYLATION 




Zika virus (ZIKV) is an emerging mosquito-borne flavivirus. Recent ZIKV 
outbreaks have produced serious human disease, including neurodevelopmental 
malformations (congenital Zika syndrome) and Guillain-Barré syndrome. These 
outcomes were not associated with ZIKV infection prior to 2013, raising the possibility 
that viral genetic changes could contribute to new clinical manifestations. Nearly all 
contemporary ZIKV isolates encode an N-linked glycosylation site in the envelope (E) 
protein (N154) but this glycosylation site is absent in many historical ZIKV isolates. 
Here, we investigated the role of E protein glycosylation in ZIKV pathogenesis using two 
contemporary Asian-lineage strains (H/PF/2013 and PRVABC59) and the historical 
African-lineage strain (MR766). We found that glycosylated viruses were highly 
pathogenic in Ifnar1-/- mice. In contrast, non-glycosylated viruses were attenuated, 
producing lower viral loads in the serum and brain when inoculated subcutaneously, but 
replicating equally well in the brain when inoculated intracranially. These results suggest 
that E glycosylation is advantageous in the periphery but not within the brain.  
____________________ 





Accordingly, we found that glycosylation facilitated infection of cells expressing DC-
SIGN and DC-SIGNR, suggesting that inefficient infection of lectin-expressing 
leukocytes could explain the attenuation of non-glycosylated ZIKV in mice. Additionally, 
we show that glycosylating the E protein at a different position (N67) does not 
functionally complement the loss of the glycan at position 154, but instead further 
attenuated the virus.  
2.2 Importance 
 
It is unclear why the ability of Zika virus (ZIKV) to cause serious disease, 
including Guillain-Barré syndrome and birth defects, was not recognized until recent 
outbreaks. One contributing factor could be genetic differences between contemporary 
ZIKV strains and historical ZIKV strains. All isolates from recent outbreaks encode a 
viral envelope protein that is glycosylated, whereas many historical ZIKV strains lack 
this glycosylation. We generated non-glycosylated ZIKV mutants from contemporary 
and historical strains and evaluated their virulence in mice. We found that non-
glycosylated viruses were attenuated and produced lower viral loads in serum and 
brains. Our studies suggest envelope protein glycosylation contributes to ZIKV 




Zika virus (ZIKV) is an emerging flavivirus primarily transmitted by mosquitoes. 
Most ZIKV infections are asymptomatic, with approximately 20% resulting in self-limiting 
illness, including maculopapular rash, fever, and/or conjunctivitis (2, 153). Historically, 
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ZIKV was not associated with significant human disease. However, recent ZIKV 
outbreaks have featured new clinical manifestations. The 2013-2014 ZIKV outbreak in 
French Polynesia was associated with an increase in Guillain-Barré syndrome, an 
autoimmune neuropathy that can result in weakness, paralysis, and death (2, 34, 35). 
The subsequent detection of ZIKV in Brazil in 2015 and the rapid spread of ZIKV to 
many countries in the Americas (33, 36–38) has revealed that ZIKV infection during 
pregnancy can cause a broad range of congenital malformations termed congenital Zika 
syndrome (2, 39, 40). 
 ZIKV is grouped into two major phylogenetic lineages, African and Asian. All 
contemporary American strains belong to the Asian lineage, and genetic analyses 
support a model of a single introduction of ZIKV to Brazil from the South Pacific (37, 38, 
127). It is unknown why severe disease manifestations such as congenital Zika 
syndrome were only revealed during the most recent ZIKV outbreak, but non-exclusive 
explanations include i) the ability of a large outbreak with good surveillance to reveal 
rare outcomes, ii) different host genetic or immune status in Latin America compared to 
regions where ZIKV circulated previously, and iii) genetic changes in ZIKV strains 
resulting in altered tropism and/or enhanced pathogenesis (154). Amino acid 
substitutions that may contribute to the increased rate of transmission and/or 
pathogenicity have been identified by comparative genomic and phylogenetic analyses 
(41, 155, 156). Differences in the non-structural protein 1 (NS1) and pre-membrane 
protein (prM) have been associated experimentally with enhanced transmission or 
virulence of American strains (127, 157–159). These analyses also have revealed a 
difference in the N-linked glycosylation motif (N-X-S/T) at amino acid 154 of the ZIKV 
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envelope (E) protein. Many African-lineage ZIKV isolates lack the glycosylation motif 
either due to a 4-6 amino acid deletion or a T156I substitution, whereas all Asian-
lineage strains, including ones from recent outbreaks, contain an intact glycosylation 
signal (29, 128). This is significant because N-linked glycosylation on E is associated 
with enhanced mosquito transmission and/or increased virulence in vertebrates for 
other flaviviruses, including West Nile virus (WNV), Japanese encephalitis virus (JEV), 
tick-borne encephalitis virus, and others (82, 95, 105, 114, 116–118, 160–163).  
 In this study, we investigated the role of E glycosylation in ZIKV pathogenesis 
across Asian- and African-lineage ZIKV strains. We used site-directed mutagenesis to 
ablate the glycosylation motif with a single amino acid substitution (N154Q) in a 
previously described infectious clone of the Asian-lineage ZIKV strain H/PF/2013 (164). 
We generated a new infectious clone of another widely used Asian-lineage ZIKV strain, 
PRVABC59, and ablated the glycosylation motif with either an N154Q or a T156I 
substitution. Finally, we used our previously reported infectious clones derived from the 
prototype African-lineage ZIKV strain MR766 TVP 14270 with a 4 amino acid deletion 
ablating the glycosylation site, as well as mutants with a restored glycosylation signal or 
4 amino acids restored with a T156I mutation ablating the glycosylation signal (164). We 
show that mutant viruses lacking E glycosylation are avirulent in Ifnar1-/- mice and are 
attenuated in overall replication in vivo. We also show that the lectins DC-SIGN and DC-
SIGNR facilitate infection of glycosylated virus in cell culture. Additionally, we show that 
the addition of a glycan at position N67 did not functionally complement the loss of 
glycosylation at N154. Our results indicate N-linked glycosylation of the ZIKV E protein 
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at position N154 mediates infection and pathogenesis and suggest the glycan may 
enhance infectivity via cell surface lectins.   
2.4 Results 
 
N154Q mutation ablates E glycosylation.  
To evaluate the role of E glycosylation in ZIKV infection, we used site-directed 
mutagenesis to introduce a single amino acid substitution (N154Q) that ablates the 
glycosylation motif (N-X-S/T) in a previously described infectious clone of ZIKV strain 
H/PF/2013 (Fig. 2.1A)(164). Consensus sequencing of virus released from 
electroporated Vero cells confirmed the two engineered nucleotide changes (Fig. 2.1B). 
We compared the growth of the H/PF/2013 isolate, wild-type (WT) clone, and N154Q 
mutant viruses in Vero cells and found equivalent replication kinetics (Fig. 2.1C).  To 
verify the glycosylation status of the viral E protein, we immunoprecipitated lysates from 
infected Vero cells with monoclonal antibody (MAb) 1M7, a human MAb that binds the 
conserved fusion loop of E. We digested the immunoprecipitates with peptide N-
glycosidase F (PNGase F) to remove all N-linked carbohydrates. When probed by 
western blot with MAb 4G2, E protein from H/PF/2013 isolate virus and WT infectious 
clones exhibited a smaller molecular weight after PNGase F treatment, indicating glycan 
cleavage (Fig. 2.1D). However, the size of the N154Q E protein was unaffected by 
PNGase F digestion, indicating that the mutant E protein was not glycosylated. 
Compared to ZIKV, DENV E protein exhibited a greater size shift upon PNGase F 
digestion, as expected because DENV E has two glycosylation sites (N67 and N153) 
(80). We further confirmed the glycosylation state of the viral E protein by lectin blot, 
using biotinylated-concanavalin A (ConA), a mannose/glucose binding lectin, to probe E 
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protein immunoprecipitated from infected Vero cells. Consistent with the results from 
PNGase F digestion, the H/PF/2013 isolate and WT clone E proteins were detected by 
ConA, whereas the N154Q E protein was not (Fig. 2.1E).  
Ifnar1 heterozygous mice are not susceptible to ZIKV disease.  
Since E glycosylation has been described as a neuroinvasion determinant of 
ZIKV and other flaviviruses (98, 117), we next evaluated the virulence of the N154Q 
mutant in mice. ZIKV does not replicate efficiently in wild-type C57BL/6 mice because 
ZIKV NS5 protein does not antagonize mouse STAT2 (131, 132). Thus, mouse models 
of ZIKV pathogenesis typically employ mice lacking IFN-αβ signaling, usually through 
genetic loss of the IFN-αβ receptor (Ifnar1-/-) alone or in combination with the IFN-γ 
receptor, or by treatment of wild-type mice with IFNAR1-blocking MAb (MAR1-5A3) 
(136, 140, 165–169). Treatment with MAR1-5A3 results in increased ZIKV viremia (with 
higher MAb doses producing higher viremia) but does not elicit the weight loss and 
lethality observed in Ifnar1-/- mice (166), implying that partial loss of IFNAR1 activity may 
allow sufficient ZIKV replication to study pathogenic phenotypes. Thus, we sought to 
determine if mice with a single copy of Ifnar1 were more susceptible to ZIKV infection 
than mice with two copies. We crossed Ifnar1+/- mice to generate mixed litters of 
Ifnar1+/+, Ifnar1+/-, and Ifnar1-/- mice, which we infected at 4 to 6 weeks of age with 1x103 
FFU of ZIKV H/PF/2013 isolate by a subcutaneous route in the footpad. Weight loss 
and lethality were measured for 14 days (Fig. 2.2 A and B). Ifnar1+/+ and Ifnar1+/- mice 
did not lose weight and did not succumb to infection, whereas Ifnar1-/- mice began losing 
weight at 5 days post-infection (dpi) and all Ifnar1-/- mice succumbed to the virus by 7 
dpi. To determine if Ifnar1+/- mice sustained increased viral replication compared to 
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Ifnar1+/+ mice in the absence of overt disease (similar to MAR1-5A3-treated mice), we 
measured viral loads in the serum at 2, 4, and 6 dpi by qRT-PCR (Fig. 2.2 C). Ifnar1+/- 
mice had similar viral loads in the serum compared to Ifnar1+/+ mice, whereas Ifnar1-/- 
mice had >100-fold higher viral loads in the serum compared to Ifnar1+/+ and Ifnar1+/- 
mice. These results indicate that one copy of Ifnar1 is sufficient to restrict ZIKV 
infection, so we used Ifnar1-/- mice for all subsequent pathogenesis experiments. 
ZIKV E N154Q is attenuated upon subcutaneous but not intracranial inoculation.  
To evaluate the role of E glycosylation in ZIKV pathogenesis we infected 5- to 6-
week old Ifnar1-/- mice with 1x103 FFU of WT or N154Q virus by a subcutaneous route 
in the footpad and evaluated weight loss and lethality (Fig. 2.3A and B).  Mice infected 
with WT clone virus began losing weight at 4 days post-infection (dpi) and all mice 
succumbed by 7 dpi, consistent with previous studies with the H/PF/2013 isolate virus 
(166). In contrast, mice infected with the N154Q virus lost weight from 5 to 7 dpi but 
recovered and all mice survived. Studies with ZIKV and other flaviviruses have identified 
a role for E glycosylation in neuroinvasion (98, 116, 117), so we tested whether the 
N154Q mutant regained virulence if the blood-brain barrier was bypassed. We infected 
WT and Ifnar1-/- mice with 1x103 FFU of WT or N154Q virus by intracranial inoculation 
and found that both viruses caused equivalent weight loss and lethality (Fig. 2.3C-E). 
Six of 7 Ifnar1-/- mice infected with the N154Q mutant died, while one mouse lost weight 
and recovered. WT mice lost weight from 4 to 6 dpi, but all mice recovered and all mice 
survived infection with both viruses. Overall, these results indicate that ZIKV N154Q 
remains neurovirulent, even though this virus was attenuated via a subcutaneous 
inoculation route.   
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ZIKV E N154Q has impaired replication in vivo.  
Since the ZIKV N154Q virus was avirulent following subcutaneous inoculation, 
but lethal upon intracranial inoculation, we tested whether E glycosylation mediated 
neuroinvasion as well as invasion into other specialized tissue compartments, such as 
the eyes and testes, compared to peripheral tissues such as the serum and spleen. We 
infected 5-week-old Ifnar1-/- mice with 1x103 FFU of WT or N154Q virus via 
subcutaneous footpad inoculation and measured viral loads in the serum at 2, 4, and 6 
dpi (Fig. 2.4.A) and viral loads in tissues 6 dpi by qRT-PCR (Fig. 2.4B-E). Compared to 
the WT virus, ZIKV N154Q produced lower viral loads in the serum at all time points, as 
well as reduced viral loads in the brain and eyes. In contrast, viral loads in the spleen 
and testes were not affected by E glycosylation. These results indicate that ZIKV 
H/PF/2013 N154Q, lacking the E glycosylation, is attenuated and produced lower 
viremia, which could contribute to lower viral loads detected in some tissues.  
Low levels of ZIKV detected in the brains of N154Q-infected mice could result 
from delayed or inefficient neuroinvasion by the non-glycosylated virus. Alternatively, 
the attenuated mutant could revert in the periphery, producing WT virus that infects the 
brain. To distinguish these possibilities, we extracted RNA from brains 6 days after 
footpad inoculation with ZIKV N154Q and evaluated viral E sequences by Sanger 
sequencing. Based on sequencing chromatograms, 7 of 10 brains contained a mixture 
of WT and N154Q virus, 1 brain contained predominantly WT virus, and 2 brains 
contained predominantly N154Q virus. To determine whether the N154Q mutant was 
stable in the periphery, we performed Sanger sequencing on RNA extracted from serum 
2 days after infection with ZIKV N154Q. We found that serum from 2 of 5 mice 
30 
 
sequenced contained a mixture of WT and N154Q virus while the N154Q mutation was 
maintained in 3 mice. We next sequenced virus from brains harvested 5 to 8 days after 
intracranial inoculation with ZIKV N154Q and found that the N154Q mutation was 
maintained in 6 of 6 mice. Altogether, these data suggest selection favoring 
glycosylated virus in peripheral tissues but not within the brain of ZIKV-infected Ifnar1-/- 
mice.  
Asian and African lineage strains lacking the E glycosylation are attenuated.  
ZIKV strain H/PF/2013 was isolated from an outbreak in French Polynesia in 
2013, which preceded the emergence of ZIKV in the Americas and only retrospectively 
was associated with cases of congenital Zika syndrome (32, 170–172). Since other 
reports of a role for E glycosylation in mediating ZIKV virulence used an African-lineage 
strain or a Cambodian strain from 2010 (99), we sought to determine if glycosylation 
mediated similar effects on virulence and tissue invasiveness in a contemporary ZIKV 
strain from Latin America. We generated a new infectious clone of another widely used 
contemporary Asian lineage strain, PRVABC59 (Puerto Rico, 2015) (Fig. 2.5A) (173). 
Due to the high nucleotide identity between H/PF/2013 and PRVABC59 (>99%), we 
were able to use the same restriction endonuclease sites to partition the viral genome 
across four plasmids, as previously described (164). Following digestion, ligation, in 
vitro transcription, and electroporation into Vero cells, infectious virus was recovered. 
The virus was passed once on Vero cells and titered by focus-forming assay. The open 
reading frame of the WT infectious clone was sequenced, and we confirmed no new 
mutations were introduced compared to the reference genome sequence for this strain 
(accession number KU501215). We used site-directed mutagenesis to introduce a 
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single amino acid substitution (N154Q) to ablate the glycosylation motif (N-X-S/T).  We 
also made a second mutant virus with the glycosylation motif ablated by a T156I 
mutation, as this variant has been detected in ZIKV strains isolated from mosquitoes in 
Africa in the 1970s and 1980s (29, 174). The region surrounding the introduced 
mutation was sequenced (Fig. 2.5B). All four viruses replicated equivalently in Vero 
cells (Fig. 2.5C).  We performed PNGase F digestion (Fig. 2.5D) and lectin blotting (Fig. 
2.5E) on immunoprecipitated E protein from Vero cells infected with PRVABC59 isolate, 
WT clone, N154Q mutant, and T156I mutant viruses to confirm the E glycosylation 
state.  PNGaseF digestion produced a size shift for the PRVABC59 isolate and WT 
clone E proteins, but not the two mutants (Fig. 2.5D). Lectin blotting showed a band for 
the PRVABC59 isolate and the WT clone E proteins, but no band was detected for the 
two mutants lacking the E glycosylation (Fig. 2.5E). These results indicate that ZIKV 
PRVABC59 isolate and WT clone E protein are glycosylated and that this glycosylation 
is ablated by either N154Q or T156I mutations.  
We next tested the virulence of the PRVABC59 viruses in Ifnar1-/- mice. We 
inoculated 5-to-6-week-old mice with 1x103 FFU of PRVABC59 isolate, WT clone, 
N154Q, or T156I viruses via subcutaneous footpad infection and measured viral loads 
in the serum at 2, 4, and 6 dpi (Fig. 2.6A) and tissues at 6 dpi by qRT-PCR (Fig. 2.6B-
E). The WT clone produced viral loads similar to the isolate virus. However, both non-
glycosylated mutants produced lower viral loads than WT viruses at all time points in the 
serum, as well as in the brain and eyes, indicating that, like strain H/PF/2013, ZIKV 
PRVABC59 infection is mediated by E protein glycosylation in vivo. Similar to strain 
H/PF/2013, glycosylation did not impact ZIKV PRVABC59 viral loads in the spleen or 
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testes. The observation that N154Q and T156I mutants produced very similar viral loads 
is consistent with a specific role for glycosylation in ZIKV infection, rather than an effect 
of the Asn residue itself.  As for experiments with ZIKV H/PF/2013, we used Sanger 
sequencing to evaluate viral E sequences from brains harvested 6 days after footpad 
infection with ZIKV PRVABC59 N154Q or T156I. In contrast to the H/PF/2013 strain, we 
found that the mutations were maintained in all 11 brains evaluated (5 N154Q and 6 
T156I). These results could indicate that E glycosylation provides a selective advantage 
for ZIKV H/PF/2013 but not PRVABC59. Alternatively, E glycosylation may be 
advantageous for both strains, but our stock of H/PF/2013 N154Q virus could contain 
revertants at a level below the sensitivity of our Sanger sequencing assay, allowing for 
more rapid selection and amplification in vivo compared to the PRVABC59 viruses.  
H/PF/2013 and PRVABC59 are both Asian-lineage ZIKV strains, closely related 
to ZIKV strains circulating in the Americas (41, 175). However, the prototype ZIKV 
strain, MR766, is an African-lineage strain isolated from a sentinel rhesus macaque in 
1947 and subsequently maintained by extensive passage in suckling mouse brains 
(~150 passages) (24). Likely due to this long history, several variants of MR766 have 
been used by different groups and non-identical sequences deposited in NCBI (50, 
176). Among the many differences in reference sequences for ZIKV strains named 
“MR766” is the glycosylation signal at N154, with some sequences encoding an intact 
glycosylation signal (accession number HQ234498.1), some with a T > I point mutation 
that ablates the glycosylation signal (accession number LC002520.1), and others with a 
4-6 amino acid deletion that ablates the glycosylation signal (accession numbers 
DQ859059.1, AY632535.2, and NC_012532.1). To determine whether different MR766 
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variants exhibited similar virulence in vivo, we compared two MR766 isolates obtained 
from the World Reference Center for Emerging Viruses and Arboviruses: TVP 14270 
(SM 150, 2/7/2011) and M4946 (SM 146 10/14/1952). By Sanger sequencing, we 
determined that M4946 had an intact glycosylation signal at N154, whereas TVP 14270 
had a 4 amino acid deletion ablating this signal. We infected 7- to 10-week old Ifnar1-/- 
mice with 1x103 FFU of MR766 isolate strains by subcutaneous footpad inoculation. 
Consistent with a role for E glycosylation in mediating ZIKV virulence, mice infected with 
M4946 (+gly) lost weight faster and exhibited 100% lethality by 9 dpi, whereas only 20% 
of mice infected with TVP14270 (-gly) succumbed (Fig. 2.7A and B). These results are 
consistent with our previous studies which used MR766 TVP14270 (-gly) (166). We 
previously reported an infectious clone derived from MR766 TVP 14270 (-gly), as well 
as mutants that restored the N154 glycosylation signal (+gly) or restored the 4 amino 
acid deletion but with the T156I mutation ablating the glycosylation signal (164). To 
compare the virulence of these isogenic mutants, we infected 5-week-old Ifnar1-/- mice 
with 1x103 FFU of MR766 +gly, -gly, and T156I clone viruses via subcutaneous footpad 
inoculation and measured viral loads in serum at 2 and 4 dpi (Fig. 2.7C), and in tissues 
at 4 dpi (Fig. 2.7C-F). Tissues were harvested at 4 dpi, rather than 6 dpi, because mice 
succumbed to the +gly virus by 5 dpi, consistent with reports of MR766 +gly being more 
pathogenic than Asian lineage strains (136) and MR766 -gly being less pathogenic than 
H/PF/2013 (166). Similar to ZIKV H/PF/2013 and PRVABC59, we observed lower viral 
loads at all time points in the serum, as well as in the brain, but not in the testes or 
spleen, with the -gly and T156I viruses, compared to mice infected with the +gly virus. In 
the eyes, we found significantly lower viral loads with the -gly virus, but not the T156I 
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virus, compared to the +gly infected mice.  Altogether, our data indicate ZIKV lacking 
the E protein glycosylation, in both African and Asian lineage strains, are attenuated 
compared to viruses with E protein glycosylation.  
Lectins DC-SIGN and DC-SIGNR mediate infection of glycosylated ZIKV.  
All non-glycosylated ZIKV that we tested (6 viruses from strains H/PF/2013, 
PRVABC59, and MR766) replicated equivalently to their glycosylated counterparts in 
Vero cells but produced significantly lower viremia in Ifnar1-/- mice. One explanation for 
the in vivo attenuation of non-glycosylated viruses is lower infectivity due to an inability 
to bind to attachment factors. The lectins DC-SIGN (CD209) and DC-SIGNR (L-SIGN or 
CD209L) mediate attachment and entry of flaviviruses including DENV (83, 177, 178), 
WNV (67, 79, 81), and JEV (82, 84). DC-SIGN is highly expressed in macrophages and 
dendritic cells, while DC-SIGNR is expressed on microvascular endothelial cells, 
especially in the liver sinusoids, lymph nodes, and placental villi (64). To test whether 
ZIKV E glycosylation facilitates lectin-mediated attachment and infectivity, we used Raji 
cells and Raji cells expressing DC-SIGN (Raji-DC-SIGN) or DC-SIGNR (Raji-DC-
SIGNR) and measured infection by flow cytometry. We confirmed that DC-SIGN and 
DC-SIGNR were expressed on the surface of the appropriate cell type, but not parental 
Raji cells (Fig. 2.8A). Cells were infected with ZIKV (strain PRVABC59) WT clone, 
N154Q mutant, T156I mutant, or UV inactivated WT clone virus at a multiplicity of 
infection (MOI) of 5 and intracellular E protein was measured 24 hours post-infection 
(hpi) by flow cytometry (Fig. 2.8B and C). No E protein signal was detected in cells 
infected with UV-inactivated virus, confirming that our assay measured viral infection 
and replication, not residual inoculum. In the absence of exogenous lectin expression, 
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Raji cells were not efficiently infected with ZIKV. However, WT ZIKV, with glycosylated 
E protein, infected Raji cells expressing exogenous DC-SIGN, and to a greater extent, 
DC-SIGNR. Infection by non-glycosylated ZIKV (N154Q or T156I) was not augmented 
by DC-SIGN expression. Unexpectedly, the N154Q mutant was able to infect DC-
SIGNR expressing cells (albeit to a lower extent than WT virus), while DC-SIGNR did 
not augment infection by the T156I mutant. Altogether, these data suggest E 
glycosylation facilitates ZIKV infection of lectin-expressing leukocytes, which could 
contribute to lower viremia produced by non-glycosylated ZIKV in vivo.  
We also used flow cytometry to measure infection of two epithelial cell lines 
commonly used in ZIKV studies, Vero and A549. Both of these cell lines lack DC-SIGN 
expression (data not shown), suggesting entry occurs via different attachment factors. 
Consistent with the equivalent replication we observed for non-glycosylated ZIKV in 
Vero cells (Fig. 2.1E and Fig. 2.5E), N154Q and T156I mutants exhibited similar 
infection efficiency in Vero cells (~75% compared to ~85% of the cell population for WT 
virus) (Fig. 2.9A and B). Compared to Vero cells, A549 cells were less permissive to all 
viruses, but infection was more dependent on E glycosylation (~5% infection with 
N154Q and T156I viruses compared to ~20% for WT) (Fig. 2.9C and D). The effect of E 
glycosylation on A549 cell infection also was evident in multi-step growth curves, which 
showed that PRVABC59 N154Q and T156I mutants were attenuated by 10 to 100-fold 
compared to the WT clone (Fig. 2.9E). Likewise, replication of the H/PF/2013 N154Q 
mutant was significantly attenuated in A549 cells compared to the WT clone (Fig. 2.9F). 
These data suggest the E glycosylation mediates ZIKV infection in A549 cells but is 
dispensable in Vero cells.  
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The number and location of ZIKV E glycosylation sites affect replication in cell 
culture.   
We next tested whether the location of the glycosylation on E affected ZIKV 
replication. Since DENV has a second glycosylation site at position N67 of E in addition 
to N154, we choose this site to add a second glycan to ZIKV E. To evaluate whether E 
glycosylation at position 67 of ZIKV could functionally complement the loss of the 
glycosylation at position 154, we used site-directed mutagenesis to introduce a 
glycosylation motif (DMA > NTT; GAC ATG GCT > AAC ACG ACA) at position 67 of the 
E protein in  ZIKV strain H/PF/2013 (generating mutant D67N) as well as on the N154Q 
background (D67N/N154Q) (Fig. 2.10A) (52). To verify the glycosylation status of the 
viral E proteins, we infected Vero and C6/36 cells with WT ZIKV or glycosylation 
mutants N154Q, D67/N154Q, or D67, or DENV. We immunoprecipitated cell lysates 
with MAb 1M7 and probed by western blot with MAb 4G2. The molecular weight of E for 
each virus was as expected, corresponding to the number of glycosylation sites present 
on each E protein (Fig 2.10B). Virus lacking glycosylation (N154Q) had the smallest E 
protein size.  WT and D67N/N154Q E proteins (each with a single glycan), were ~2kD 
larger than N154Q, while D67N E protein (two glycans) was ~4kD larger than N154Q. 
ZIKV D67N E protein was similar in size to DENV, which naturally is glycosylated at 
both D67 and N153. Mammalian and mosquito cell derived viruses produced similar 
size patterns, indicating similar utilization of E protein glycosylation sites in both cell 
types. We further verified the glycosylation status of each viral E protein by lectin blot 
using ConA. WT ZIKV, D67N/N154Q, D67N, and DENV E proteins were detected by 
ConA, whereas the N154Q E protein was not (Fig. 3.1B). We next compared the growth 
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kinetics of the H/PF/2013 isolate, WT clone, N154Q mutant, D67N/N154Q mutant, and 
D67N mutant viruses in Vero, A549, and C6/36 cells (Fig. 2.10C-E). In Vero cells, the 
isolate, WT clone and N154Q mutant replicated equivalently, whereas D67N/N154Q 
and D67N were both attenuated by ~1000-fold at 24, 48 and 72 hpi. In A549 cells, the 
isolate and WT clone replicated equivalently, whereas the N154Q mutant was 
attenuated by about ~100-fold at all time points, and the D67N/N154Q and D67N 
mutants were further attenuated, by ~10,000 fold compared to the WT clone. In C6/36 
cells, the isolate, WT clone, N154Q mutant, and D67N/N154Q mutant all replicated 
equivalently, while the D67N mutant was attenuated by ~10-100-fold at all time points. 
These data indicate having two glycans on ZIKV E severely attenuates the virus in all 
cell types tested, while having a single glycan at position N67 is attenuating in Vero and 
A549 cells, but tolerated in C6/36 cells, suggesting the number and position of the 
glycan on E effects ZIKV replication in a cell-type specific manner.  
To further analyze the effect of the location of E glycosylation on ZIKV 
replication, we measured infection by flow cytometry of Vero, A549, Raji, Raji-DC-SIGN, 
and Raji-DC-SIGNR cells (Fig 2.11A-C). Cells were infected at a MOI of 1 with ZIKV 
H/PF/2013 WT, N154Q, D67N/N154Q, or D67N virus derived from C6/36 cells. Cells 
were stained at 24 hpi with Alexa Fluor 488-conjugated ZIKV MAb 4G2 to detect 
intracellular E protein. In Vero cells, WT virus infected ~60% of the cells, while N154Q 
infected ~75%, D67N/N154Q infected ~80%, and D67N infected ~90% of cells. In A549 
cells, WT virus infected ~25% of the cells, while N154Q infected ~12%, and 
D67N/N154Q infected ~19% of the cells. Surprisingly, D67N had the highest infectivity 
in A549 cells of ~40%. The Vero and A549 flow cytometry data matches the replication 
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seen in our multistep growth curves, with the exception of the D67N virus in A549 cells, 
which replicated poorly at all time points compared to WT, but had the highest level of E 
positive cells at 24 hpi by flow cytometry. In the absence of exogenous lectin 
expression, Raji cells were not efficiently infected with ZIKV. However, WT ZIKV, with 
glycosylation at position N154 of E protein, infected Raji cells expressing exogenous 
DC-SIGN, and to a greater extent, DC-SIGNR. Infection by non-glycosylated N154Q 
was not augmented by DC-SIGN expression, but the N154Q mutant was able to infect 
DC-SIGNR expressing cells (albeit to a lower extent than WT virus), consistent with 
previous experiments using the PRVABC59 strain. The single glycosylated 
D67N/N154Q and the double glycosylated D67N viruses showed significantly higher 
levels of infected cells in both Raji-DC-SIGN and Raji-DC-SIGNR compared to WT 
virus. 
E glycosylation at position N67 does not functionally complement the loss of 
glycosylation at position N154 for ZIKV replication in mice.  
 We next tested whether glycosylation at N67 of E can functionally complement 
the loss of glycosylation at position N154 in wild-type mice pre-treated with an IFNAR1-
blocking MAb. We injected 5-to-6-week-old mice with 2mg of MAb MAR1-5A3 
intraperitoneally and infected one day later with 1 x 103 FFU of H/PF/2013 WT clone, 
N154Q, D67N/N154Q, or D67N viruses via a subcutaneous route in the footpad and 
measured viral loads in the serum at 2 dpi by qRT-PCR (Fig 2.11A). Compared to the 
WT virus, ZIKV N154Q produced ~10-100-fold lower viral loads in the serum, while 
D67N/N154Q and D67N were further attenuated by an additional ~10-fold. These data 
indicate the addition of a glycosylation site at position N67 of E does not functionally 
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complement the loss at N154, and, in mice, attenuates the virus more than having no E 
glycosylation.  
Altogether, our results demonstrate that it is not the case that ZIKV simply 
requires a glycan anywhere on E, but rather that glycosylation at position 154 of E is 
important for ZIKV infection in a cell type-specific manner, which may result from 
augmented infection of cells expressing certain cell-surface lectins. 
2.5 Discussion 
 
The emergence of ZIKV in the Western Hemisphere has been associated with 
new clinical manifestations including Guillain-Barre syndrome and congenital Zika 
syndrome (2). Phylogenetic analyses of ZIKV isolates from past and recent outbreaks 
have revealed amino acid differences between historic African-lineage strains and the 
contemporary Asian-lineage strains that are currently circulating in the Western 
Hemisphere (41, 155, 179). Several of these amino acid differences have been 
implicated in transmission, immune suppression, and enhanced disease. A single amino 
acid substitution (A188V) in NS1 has been shown to enhance ZIKV antigenemia in mice 
and infectivity of Aedes aegypti mosquitoes (157) and also inhibits IFN-β production in 
vitro (158). A single amino acid substitution in prM (S139N) has been shown to increase 
ZIKV replication in human neural progenitor cells and may contribute to a more severe 
microcephalic phenotype in mice (159), although others found that this mutation is not 
essential for fetal pathology in a mouse transplacental transmission model (180).  
 Nearly all contemporary Asian-lineage strains possess an intact E glycosylation 
motif at N154. However, in 2016, a non-glycosylated (4 AA Δ) Asian-lineage ZIKV strain 
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(AFMC-U; accession no. KY553111), was isolated from the urine of a male recruit in a 
Korean Army training center in the Republic of Korea (181). In contrast, many historic 
African-lineage ZIKV strains lack this motif (29, 174), though limited sampling of African 
ZIKV strains precludes robust conclusions about how common non-glycosylated viruses 
are in nature. E glycosylation plays a role in attachment and infectivity for DENV (83), 
WNV (67, 81, 96), and JEV (84) and has been associated with enhanced mosquito 
transmission and/or increased virulence and neuroinvasion in vertebrates for other 
flaviviruses (82, 95, 105, 107, 114, 116–118, 161, 162). We investigated the role of the 
ZIKV E glycosylation in tissue tropism and pathogenesis in an immunocompromised 
mouse model. Our results indicate that both Asian and African lineage ZIKV strains 
lacking E glycosylation sustained lower tissue viral loads compared to WT virus. These 
results are consistent with other reports of a role for E glycosylation in mediating ZIKV 
virulence. Annamalai et al. showed that ZIKV strain MR766 lacking E glycosylation due 
to a 4 amino acid deletion or a N154A substitution produced lower viral loads in serum 
and brains of A129 mice compared to glycosylated virus (98). Similarly, Fontes-Garfias 
et al. showed that a Cambodian ZIKV strain lacking E glycosylation due to a N154Q 
substitution also resulted in decreased viral loads in serum of A129 mice compared to 
the WT glycosylated virus (99). Notably, even though we found that ZIKV lacking E 
glycosylation resulted in lower viral loads in the serum, eyes, and brains compared to 
glycosylated virus, we observed similar viral loads in the spleen and testes, consistent 
with a previous report that glycosylated and non-glycosylated ZIKV strain MR766 
sustained similar viral loads in the spleen and liver (98). Likewise, a non-glycosylated 
mutant of Tembusu virus produced equivalent viral loads in the spleens of infected 
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ducks, despite reduced viral loads in other tissues (114). Furthermore, our observation 
that the ZIKV H/PF/2013 N154Q mutation was maintained upon intracranial inoculation, 
but selected against after subcutaneous inoculation, suggests that glycosylation 
provides a selective advantage to ZIKV in peripheral tissues but not within the brain. 
Altogether, these observations suggest E glycosylation facilitates infection of ZIKV, and 
perhaps other flaviviruses, in a tissue or cell type-specific manner.  
 E glycosylation likely facilitates attachment to and infection of lectin-
expressing cells, including CD14+ monocytes cells that are targets of ZIKV in humans 
(182–185). DC-SIGN and DC-SIGNR are among several attachment factors described 
for flaviviruses such as DENV (83, 177, 186), JEV (82, 84), and WNV (67, 81, 96) as 
well as for ZIKV (85, 187, 188), though it is less clear which lectins or other attachment 
factors actually mediate ZIKV infection in mice or humans (189–191). Though mice do 
not have clear DC-SIGN or DC-SIGNR orthologs, they have eight DC-SIGN homologs 
clustered within the same genomic region (182). According to their glycan specificity, 
murine SIGNR1 and SIGNR3 are the closest candidates to fulfill DC-SIGN function in 
mice, but their ability to facilitate flavivirus infection is unclear. Unexpectedly, we found 
DC-SIGNR was able to augment infection by the N154Q mutant, even in the absence of 
E glycosylation, which was unlike the T156I mutant. The different infection efficiencies 
of the two non-glycosylated mutants on Raji DC-SIGNR cells could result from less 
efficient maturation of N154Q virions compared to T156I virions; in this case, 
glycosylated prM on immature N154Q virions may partially complement the loss of E 
glycosylation (188). Cleavage of prM is required to produce mature infectious virions, 
because interactions between prM and E prevent the conformational changes required 
42 
 
to drive pH-dependent membrane fusion, but partially mature virions also can be 
infectious (20). The cleaved portion of prM is glycosylated and uncleaved prM on 
partially mature virions can facilitate attachment and entry in a DC-SIGNR-dependent 
manner (81, 188). Alternatively, the difference in infection efficiencies in DC-SIGNR 
cells could indicate a specific role for Gln 154 or Thr 156 independent of glycosylation, 
perhaps through modulation of the glycan loop and resulting effects on attachment and 
fusion (188, 191). For example, different amino acid substitutions at E154/156 of WNV 
conferred distinct avian host and vector competence phenotypes independent of E-
protein glycosylation status (101).  
 The location and number of glycosylation sites on E have been shown to 
impact attachment and infection for WNV and JEV (79, 82).  We show that the addition 
of a glycan at position N67 of ZIKV E impacts attachment, infectivity, and replication in 
lectin-expressing leukocytes and A549 cells, but had minimal impact in Vero cells. The 
addition of a glycan at position N67 was unable to functionally complement the loss of 
the glycan at position N154.  Distinct glycosylation profiles also could have an impact on 
the host Ab response. This is significant because ZIKV is circulating in DENV endemic 
regions, and the similarity between the two flavivirus could impact cross-reactive Ab 
responses. Overall, our findings demonstrate a role for E glycosylation, specifically at 
position N154, in ZIKV pathogenesis, possibly by facilitating attachment and infection of 
lectin-expressing leukocytes.  
2.6 Materials and methods  
 
Cells and viruses. Vero and A549 cells were maintained in Dulbecco’s modified 
Eagle medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS) and 
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L-glutamine at 37oC with 5% CO2.  Raji, Raji-DC-SIGN, and Raji-DC-SIGNR cells were 
obtained from Dr. Ted Pierson (NIH). Raji cells were maintained in RPMI 1640 media 
supplemented with 10% FBS and penicillin/streptomycin. ZIKV strains H/PF/2013 and 
PRVABC59 were provided by the U.S. Centers for Disease Control and Prevention 
(172, 173). The ZIKV MR766 strains were obtained from the World Reference Center 
for Emerging Viruses and Arboviruses (24, 50, 176). DENV-3 WHO Reference strain 
(CH54389) was obtained from Dr. Aravinda de Silva (UNC) (192). Virus stocks were 
grown in Vero (African green monkey kidney epithelial) cells.  Virus stocks were titered 
on Vero cells by focus-forming assay (FFA) (193). For multi-step growth analysis, cells 
were infected at a MOI of 0.01 and incubated at 37oC with 5% CO2. Samples of infected 
cell culture supernatant were collected at 4, 24, 48 and 72 hpi and stored at -80oC for 
virus titration. Virus quantification was performed by FFA on Vero cells. Duplicates of 
serial 10-fold dilutions of virus in viral growth medium (DMEM containing 2% FBS and 
20 mM HEPES) were applied to Vero cells in 96-well plates and incubated at 37oC with 
5% CO2 for 1 hr. Cells were then overlaid with 1% methylcellulose in minimum essential 
medium Eagle (MEM). Infected cell foci were detected 42-46 hpi. Following fixation with 
2% paraformaldehyde for 1 hr at room temperate, plates were incubated with 500 ng/ml 
of flavivirus cross-reactive mouse MAb E60 (194) for 2 hr at room temperature or 
overnight at 4oC. After incubation at room temperate for 2 hr with a 1:5,000 dilution of 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sigma), foci were 
detected by addition of TrueBlue substrate (KPL). Foci were quantified with a CTL 
Immunospot instrument. To prepare UV-inactivated virus, 20ml of PRVABC59 WT clone 
virusat 1 x105 FFU/mL was placed in a petri dish and exposed to UV light at 0.9 J/cm2 
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for 10 minutes in a HL-2000 HybriLinker (UVP Lab Products); inactivation was 
confirmed by FFA.  
ZIKV infectious clone design and mutagenesis. We used a quadripartite 
unidirectional molecular clone strategy as previously described (164), to generate a new 
infectious clone of ZIKV strain PRVABC59. Due to the high sequence similarity between 
H/PF/2013 and PRVABC59 we were able to use the same naturally occurring class IIG 
nonpalindromic restriction endonuclease sites within the full-length genome as previously 
described for ZIKV strain H/PF/2013 (164). NotI and EcoRV restriction endonuclease 
sites followed by a T7 promoter sequence, for in vitro transcription, were added to the 
immediate 5’ end of the genome. A hepatitis delta virus (HDV) ribozyme sequence, to 
generate an intact 3’ UTR, followed by a SmaI restriction endonuclease site were added 
directly after the last nucleotide of the genome. The four subgenomic fragments were 
synthesized into the pUC-57 vector (BioBasic) and amplified in One Shot TOP10 
Chemically Competent E. Coli. cells (Thermo) grown on LB plates with carbenicillin at 
37oC for ~16 hrs. Individual colonies were picked, grown to high concentrations in 
selective LB, purified (Qiagen Mini-spin kit), and sequenced. The resulting purified 
plasmids were digested, ligated, in vitro transcribed, and electroporated into Vero cells as 
previously described (195). Supernatants from electroporated Vero or C6/36 cells were 
harvested after 6 to 7 days and passaged once on Vero cells or C6/36 cells to generate 
virus stocks. Virus stocks were titered by FFA on Vero cells. Site-directed mutagenesis 
was used to introduce a single amino acid substitution (N154Q, T156I, or D67N) in the 
envelope protein to ablate the glycosylation motif. Restriction enzymes and Phusion High 
Fidelity PCR kit were obtained from New England BioLabs. SuperScript III First Strand 
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Synthesis kit was obtained from Invitrogen. Oligonucleotide primers and probes for DNA 
amplification, qRT-PCR, and sequencing were obtained from Sigma and IDT. The 
mMachine T7 Ultra transcription kit was obtained from Ambion. 
Glycosylation assays. Anti-flavivirus MAbs E60, 1M7, and 4G2  were produced 
by the UNC Protein Expression and Purification Core Facility (194, 196, 197).  E protein 
was immunoprecipitated from infected Vero cell lysates using MAb 1M7 (1µg) and 
magnetic protein A/G beads (Pierce). Immunoprecipitated E protein was digested with 
peptide N- glycosidase F (PNGaseF; New England BioLabs) according to the 
manufacturer’s protocol with a minor modification. Instead of denaturation in the 
provided glycoprotein denaturation buffer containing dithiothreitol, immunoprecipitates 
were denatured in 0.5% SDS, because the epitope recognized by MAb 4G2 is sensitive 
to reducing state (198). PNGaseF digestions were separated by SDS-PAGE (7.5% 
precast polyacrylamide gels, BioRad) under non-reducing conditions and analyzed by 
western or lectin blot. Proteins were transferred to a nitrocellulose membrane using a 
Trans-Blot Turbo Transfer System (BioRad).  In western blots, E protein was detected 
using MAb 4G2 as a primary antibody and HRP-conjugated goat anti-mouse IgG as a 
secondary antibody. For lectin blots, glycosylated E was detected with the biotinylated 
lectin concanavalin A (ConA) (Vector Laboratories), followed by HRP-conjugated 
streptavidin. Pierce ECL western blotting substrate was used to detect HRP (Thermo). 
Western and lectin blots were imaged on a ChemiDoc XRS+ system (BioRad). 
Mouse experiments. Animal husbandry and experiments were performed under 
the approval of the University of North Carolina at Chapel Hill Institutional Animal Care 
and Use Committee. Five - to six-week old or 8- to10-week-old male and female wild-
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type or Ifnar1-/- mice on a C57BL/6 background were used. MAR1-5A3 (134, 199) was 
administered intraperitoneally in a volume of 300μl. Mice were inoculated with 1x103 
FFU of ZIKV in a volume of 50μl subcutaneously (footpad) or 25μl intracranially. 
Survival and weight loss were monitored for 14 or 21 days. Animals that lost >30% of 
their starting weight or that became moribund were euthanized. 
Measurement of viral loads. ZIKV-infected mice were sacrificed at 4 or 6 dpi 
and perfused with 20 ml of PBS. Spleen, kidney, testes, brain, and eyes were harvested 
and homogenized with zirconia beads (BioSpec) in a MagNA Lyser instrument (Roche 
Life Science) in 500μl (eyes) or 1ml (all other tissues) of buffer RLT (Qiagen). Blood 
was collected at 2 and 4 dpi by submandibular bleeds with a 5mm Goldenrod lancet and 
by cardiac puncture at 6 dpi. Blood was collected in serum separator tubes (BD) and 
serum was separated by centrifugation at 8000rpm for 5 min. Tissues and serum from 
infected animals were stored at -80oC until RNA isolation. RNA was extracted with the 
RNeasy Mini Kit (tissues) or Viral RNA Mini Kit (serum) (Qiagen). ZIKV RNA levels were 
determined by TaqMan one-step quantitative reverse transcription PCR (qRT-PCR) on 
a CFX96 Touch Real-Time PCR Detection System (BioRad) using standard cycling 
conditions. Viral burden is expressed on a Log10 scale as either viral RNA equivalents 
per ml after comparison with a standard curve produced using serial 10-fold dilutions of 
RNA extracted from a ZIKV stock or genome copies per ml after comparison with a 
standard curve produced using serial 100-fold dilutions of ZIKV A plasmid. A previously 
published primer set was used to detect ZIKV H/PF/2013 and PRVABC59 RNA: 
forward, CCGCTGCCCAACACAAG; reverse, CCACTAACGTTCTTTTGCAGACAT; 
probe, /56-FAM/AGCCTACCT/ZEN/TGA CAAGCAATCAGACACTCAA/3IABkFQ/ 
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(Integrated DNA Technologies) (200). ZIKV MR766 RNA was detected using the 
following primers: forward, GGGCGTGTCATATTCCTTGT; reverse, 
TCCATCTGTCCCTGCATACT; probe, /56-
FAM/AGCCTACCT/ZEN/TGACAAGCAATCAGACACTCAA/3IABkFQ/ (Integrated DNA 
Technologies). 
Flow cytometry. Cells (2x104) were infected with ZIKV at a MOI of 5 for 1hr at 
37°C in RPMI 1640 or DMEM supplemented with 2% FBS. The cells subsequently were 
washed with FACS buffer (PBS + 1% FBS) to remove excess virus and incubated at 
37°C for 24 hrs. Following incubation, cells were washed with FACS buffer and fixed by 
adding 100ul 1% PFA and incubating at 4°C for 10 min. Cells were subsequently 
washed and permeabilized with permeabilization buffer (BSA + saponin). The 
permeabilized cells were stained for ZIKV E protein using monoclonal antibody 4G2 
conjugated to Alexa Fluor-488, diluted 1:200, for 30 min at 4°C. For extracellular 
staining, cell surface DC-SIGN and DC-SIGNR were stained using monoclonal antibody 
clone 9E9A8 for DC-SIGN (BioLegend) and MAB162 for DC-SIGNR (R&D Systems) at 
4°C for 30 min. After washing with FACS buffer, cells were fixed and permeabilized as 
above. The permeabilized cells were stained with secondary anti-IgG-PerCP, diluted 
1:100. The stained cells were subsequently washed and analyzed by flow cytometry 
using a Guava EasyCyte HT flow cytometer (Millipore).  
Data analysis. All data were analyzed with GraphPad Prism software. Flow 
cytometry data were analyzed with FlowJo V10 software. Kaplan-Meier survival curves 
were analyzed by the log rank test, and weight losses were compared using two-way 
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ANOVA. For viral burden analysis, the log-transformed titers were analyzed by the 






Figure 2.1. E glycosylation is not required for ZIKV replication. A. ZIKV envelope 
protein, depicting the nucleotide and amino acid residues of the glycosylation site, and 
N154Q mutation. B. Sequence chromatograms of E protein glycosylation site of wild-type 
(WT) and N154Q viruses. C. Vero cells were infected at a MOI of 0.01 with ZIKV 
H/PF/2013 isolate, WT clone, or N154Q mutant. Virus in culture supernatant was titered 
by focus-forming assay.  Data shown are the means ± SEM of 9 samples from 3 
independent experiments. D and E. E proteins were immunoprecipitated with MAb 1M7 
from lysates of Vero cells infected with ZIKV H/PF/2013 isolate, WT clone, N154Q mutant, 
or DENV. D. Lysates were treated with PNGase F, separated by non-reducing SDS-
PAGE, and probed with MAb 4G2. E. Lysates were separated by non-reducing SDS-





Figure 2.2. One copy of Ifnar1 is sufficient to protect mice against ZIKV 





), and homozygous knockout mice (Ifnar1
-/-
). 
Four- to six-week-old mice were inoculated with 1x10
3
 FFU of ZIKV strain H/PF/2013 
isolate by a subcutaneous route in the footpad. A. Mice were weighed daily and 
weights are expressed as percentage of body weight prior to infection. Results shown 
are the mean ± SEM of the indicated number of mice per group. Weights were 
censored once one mouse in the group died. B. Lethality was monitored for 14 days. 
C. Blood was collected at 2, 4, and 6 days after infection by submandibular bleed and 
ZIKV RNA in serum was measured by qRT-PCR. Mice per group were combined 






Figure 2.3. ZIKV E N154Q is attenuated upon subcutaneous but not intracranial 
inoculation. Five- to six –week old Ifnar1
-/- 
or wild-type (WT) mice were inoculated with 
1x10
3
 FFU of ZIKV strain H/PF/2013 WT clone or N154Q mutant by a subcutaneous (A 
and B) or intracranial (C-E) route. Mice were weighed daily and weights are expressed 
as percentage of body weight prior to infection. Results shown are the mean ± SEM of 6-
8 Ifnar1
-/- 
mice or 3 WT mice per virus from two or three independent experiments. 
Lethality was monitored for 14 days. 
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Figure 2.4. N154 glycosylation mediates ZIKV infection in mice. Five- to six –week 
old Ifnar1
-/- 
mice were inoculated with 1x10
3
 FFU of ZIKV strain H/PF/2013 WT clone or 
N154Q mutant by a subcutaneous route in the footpad. A. Blood was collected at 2, 4, 
and 6 days after infection and ZIKV RNA in serum was measured by qRT-PCR. B-E. Mice 
were euthanized 6 days after infection, perfused, and tissues were harvested. ZIKV RNA 
in tissue was measured by qRT-PCR. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, 





Figure 2.5. Generating an infectious clone of ZIKV PRVABC59 and non-
glycosylated mutants. A. An infectious clone of ZIKV strain PRVABC59 was generated 
using a system that divides the viral genome into 4 fragments flanked by the indicated 
restriction endonucleases sites. Numbers above fragments indicate nucleotide position in 
the viral genome. T7 promoter and a hepatitis delta virus (HDV) ribozyme sequences 
flank the genome. B. Sequence chromatograms of E protein glycosylation site of WT, 
N154Q, or T156I clones. C. Vero cells were infected at a MOI of 0.01 with ZIKV 
PRVABC59 isolate, WT clone, N154Q mutant, or T156I mutant. Virus in culture 
supernatant was titrated by focus-forming assay. Data shown are the mean ± SEM of 9 
samples from 3 independent experiments. D and E. E proteins were immunoprecipitated 
with MAb 1M7 from lysates of Vero cells infected with ZIKV PRVABC59 isolate, WT clone, 
N154Q mutant, and T156I mutant. D. Lysates were treated with PNGase F, separated by 
non-reducing SDS-PAGE, and probed with MAb 4G2. E. Lysates were separated by non-





Figure 2.6. E glycosylation mediates ZIKV PRVABC59 infection in mice. Five- to six 
–week old Ifnar1
-/- 
mice were inoculated with 1x10
3
 FFU of ZIKV strain PRVABC59 isolate, 
WT clone, N154Q mutant, or T156I mutant by a subcutaneous route in the footpad. A. 
Blood was collected at 2, 4, and 6 days after infection and ZIKV RNA in serum was 
measured by qRT-PCR. B-E. Mice were euthanized 6 days after infection, perfused, and 
tissues were harvested. ZIKV RNA in tissues was measured by qRT-PCR. Data are 
combined from 2 independent experiments. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; 





Figure 2.7. E glycosylation mediates ZIKV MR766 infection in mice. A-B. Seven- to 
ten-week old Ifnar1
-/- 
mice were inoculated with 1x10
3
 FFU of ZIKV strain MR766 isolate 
containing the E glycan (+gly) or lacking the E glycan (-gly [4AAΔ)] by a subcutaneous 
route in the footpad. Mice were weighed daily and weights are expressed as percentage 
of body weight prior to infection and censored once one mouse in a group died. Results 
shown are the mean ± SEM of 14 to 16 Ifnar1
-/- 
mice per virus. Lethality was monitored 
for 21 days. C-G. Five-week-old Ifnar1
-/- 
mice were inoculated with 1x10
3
 FFU of ZIKV 
strain MR766 +gly clone, -gly clone (4AAΔ), or T156I clone by a subcutaneous route in 
the footpad. C. Blood was collected at 2 and 4 days after infection and ZIKV RNA in 
serum was measured by qRT-PCR. D-G. Mice were euthanized 4 days after infection, 
perfused, and tissues were harvested. ZIKV RNA in tissues was measured by qRT-





Figure 2.8. E glycosylation facilitates ZIKV infection of DC-SIGN and DC-SIGNR 
expressing cells.  A. Representative flow plots of Raji, Raji-DC-SIGN and Raji-DC-
SIGNR cells stained for cell surface DC-SIGN and DC-SIGNR. B. Representative flow 
plots of Raji, Raji-DC-SIGN, and DC-SIGNR cells infected at a MOI of 5 with ZIKV 
PRVABC59 WT, N154Q, T156I, or UV-inactivated WT virus. Cells were stained at 24 hpi 
with Alexa Fluor 488-conjugated ZIKV MAb 4G2 to detect intracellular E protein. Values 
indicate the proportion of cells staining positive. C. Percentage of infected (E positive) 
Raji, Raji-DC-SIGN, or DC-SIGNR cells combined from 3 independent experiments 






Figure 2.9. E glycosylation facilitates ZIKV infection of A549 but not Vero cells. A-
D. Vero and A549 cells were infected at a MOI of 5 with ZIKV PRVABC59 WT, N154Q, or 
T156I clones. Cells were stained at 24 hpi with Alexa Fluor 488-conjugated ZIKV MAb 
4G2 to detect intracellular E protein. A and C. Representative flow plots of infected Vero 
or A549 cells. B and D. Percentage of infected (E positive) Vero or A549 cells combined 
from 3 independent experiments performed in triplicate. E and F. A549 cells were infected 
at a MOI of 0.01 with ZIKV PRVABC59 WT clone, N154Q mutant, and T156I mutant or 
ZIKV H/PF/2013 WT clone and N154Q mutant. Virus in culture supernatant was titrated 





Figure 2.10. The number and location of ZIKV E glycosylation sites affects replication 
in cell culture. A. Predicted glycosylation of ZIKV envelope protein mutants (red letters).  
B. E proteins were immunoprecipitated with MAb 1M7 from lysates of Vero or C6/36 cells 
infected with ZIKV H/PF/2013 WT clone, N154Q mutant, D67N/N145Q mutant, D67N 
mutant, or DENV.  Lysates were separated by nonreducing SDS-PAGE, and probed with 
MAb 4G2 or ConA. C-E. Vero, A549, and C6/36 cells were infected at a MOI of 0.01 with 
ZIKV H/PF/2013 isolate, WT clone, N154Q mutant, D67N/N154Q mutant, or D67N mutant 
virus. Viruses in culture supernatants were titrated by focus-forming assay. Data shown are 





     Figure 2.11. The location and number of glycans on E effect ZIKV replication in 
vitro and in vivo. A-C Percentage of infected (E positive) Vero, A549, or Raji, Raji-
DC-SIGN, and DC-SIGNR cells from 3 independent experiments performed in 
triplicate.  Cells were infected at a MOI of 1 with ZIKV H/PF/2013 WT, N154Q, 
D67N/N154Q, or D67N virus. Cells were stained at 24 hpi with Alexa Fluor 488-
conjugated ZIKV MAb 4G2 to detect intracellular E protein. Values indicate the 
proportion of cells staining positive. D Five- to six –week old WT mice were pre-
treated with 2mg MAR1, then inoculated with 1x10
3
 FFU of ZIKV strain H/PF/2013 
WT clone, N154Q mutant, D67N/N154Q mutant, or D67N mutant by a subcutaneous 
route in the footpad. Blood was collected at 2 days after infection and ZIKV RNA in 
serum was measured by qRT-PCR. ***, P < 0.001; ****, P < 0.0001; (unpaired 2-






CHAPTER 3 – TWO GENETIC DIFFERENCES BETWEEN 
CLOSELY-RELATED ZIKA VIRUS STRAINS DETERMINE 




Recent Zika virus (ZIKV) outbreaks and unexpected clinical manifestations of ZIKV 
infection have prompted an increase in ZIKV-related research. Here we identify two 
strain-specific determinants of ZIKV virulence in mice. We found that H/PF/2013 caused 
100% lethality in Ifnar1-/- mice, whereas PRVABC59 caused no lethality; both strains 
caused 100% lethality in Ifnar1-/- Ifngr1-/- DKO mice. Deep sequencing revealed a high-
frequency variant in PRVABC59 not present in H/PF/2013: a G to T change at nucleotide 
1965 producing a Val to Leu substitution at position 330 of the viral envelope (E) protein. 
We show that the V330 variant is lethal on both strains, whereas the L330 variant is 
attenuating only on the PRVABC59 background. These results identify a balanced 
polymorphism in the E protein that is sufficient to attenuate the PRVABC59 strain, but not 
H/PF/2013. The consensus sequences of H/PF/2013 and PRVABC59 differ by 3 amino 
acids, but these were not responsible for the difference in virulence between the two 
strains.  
_____________________ 




H/PF/2013 and PRVABC59 differ by an additional 31 non-coding or silent 
nucleotide changes. We made a panel of chimeric viruses with identical amino acid 
sequences, but nucleotide sequences derived from H/PF/2013 or PRVABC59. We found 
that 6 nucleotide differences in the 3’ quarter of the H/PF/2013 genome were sufficient to 
confer virulence in Ifnar1-/- mice. Altogether, our work identifies a large and previously 
unreported difference in virulence between two commonly used ZIKV strains, in two 




Contemporary ZIKV strains are closely related and often used interchangeably in 
laboratory research. Here we identify two strain-specific determinants of ZIKV virulence 
which are evident only in Ifnar1-/- mice, not Ifnar1-/- Ifngr1-/- DKO mice. These results 
identify a balanced polymorphism in the E protein that is sufficient to attenuate the 
PRVABC59 strain, but not H/PF/2013. We further identify a second virulence determinant 
in the H/PF/2013 strain, which is driven by the viral nucleotide sequence, not the amino 
acid sequence. Altogether, our work identifies a large and previously unreported 
difference in virulence between two commonly used strains of ZIKV, in two widely used 
mouse models of ZIKV pathogenesis. Our results highlight that even very closely related 








Zika virus (ZIKV) is a mosquito-transmitted flavivirus belonging to the Flaviviridae 
family of positive-sense single-stranded RNA viruses. ZIKV is related to other pathogenic 
flaviviruses, including dengue (DENV), yellow fever (YFV), West Nile (WNV), Japanese 
encephalitis (JEV), and tick-borne encephalitis (TBEV) viruses. Historically, ZIKV has 
been associated with a self-limiting rash and febrile illness that resolves within a few days, 
and these symptoms only occur in ~20% of infected individuals (2, 201). However, new 
clinical manifestations associated with recent ZIKV outbreaks, including Guillain-Barré 
syndrome and congenital Zika syndrome, have stimulated a surge in ZIKV research (2, 
34, 39, 40).  
Since the spread of ZIKV to the Western Hemisphere, numerous ZIKV strains have 
been isolated from patients and mosquitoes and distributed to laboratories across the 
world. Some widely-used strains include FSS13025 which was isolated in 2010 from 
patient serum in Cambodia, H/PF/2013 which was isolated in 2013 from patient serum in 
French Polynesia, PRVABC59 which was isolated in 2015 from patient serum in Puerto 
Rico, Paraiba_01/2015 which was isolated in 2015 from patient serum in Brazil, and Mex-
2-81 which was isolated in 2016 from an Aedes mosquito in Mexico (31, 170, 173, 202). 
All of these strains share high nucleotide identity (at least 98.6% identity between any two 
strains), and minimal amino acid differences throughout their genomes. Thus, these 
closely related contemporary strains have been used largely interchangeably, and results 
from studies using various strains have been compared and combined to draw overall 
conclusions about the pathogenesis of contemporary ZIKV strains. Furthermore, various 
immunodeficient mouse models are used to study ZIKV pathogenesis, and the two most 
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commonly used systems (Ifnar1-/- mice and Ifnar1-/- Ifngr1-/- DKO mice) largely have been 
assumed to yield comparable results. Ifnar1-/- mice lack the type I interferon (IFN-αβ) 
receptor, whereas Ifnar1-/- Ifngr1-/- DKO mice lack both the IFN-αβ receptor and the type 
II interferon (IFN-γ) receptor. (203).  
In this study we identified two strain-specific determinants of ZIKV virulence that 
are evident only in Ifnar1-/- mice, not Ifnar1-/- Ifngr1-/- DKO mice. We identified a balanced 
polymorphism in the E protein that is sufficient to attenuate the PRVABC59 strain, but not 
H/PF/2013. Furthermore, we identified a second virulence determinant in the H/PF/2013 
strain that is driven by the viral nucleotide sequence, not the amino acid sequence. 
3.4 Results 
 
ZIKV strains H/PF/2013 and PRVABC59 have distinct lethality phenotypes in Ifnar1-
/- mice.  
ZIKV strain H/PF/2013 was isolated from patient serum from a 2013 outbreak in 
French Polynesia and ZIKV strain PRVABC59 was isolated from patient serum from a 
2015 outbreak in Puerto Rico (170, 173). Deposited consensus sequences for these ZIKV 
strains (Genbank accession numbers KJ776791, KU501215) as well as Sanger 
sequencing of our lab stocks of H/PF/2013 and PRVABC59 (52, 164) show that these 
two strains are very similar: they share >99% nucleotide identity (34 nucleotide 
differences across the genome) and have only 3 amino acid differences (one in capsid 
and two in NS5). Both strains have been used widely and largely interchangeably by 
many research groups studying ZIKV virology and pathogenesis (52, 85, 138, 164, 188, 
204–208). However, we found that H/PF/2013 and PRVABC59 have distinct lethality 
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phenotypes in Ifnar1-/- mice (Fig. 3.1). We infected 5- to 6-week-old Ifnar1-/- mice with 1 x 
103 focus-forming units (FFU) of ZIKV H/PF/2013 or PRVABC59 by a subcutaneous route 
in the footpad and evaluated weight loss and lethality (Fig. 3.1A and B). These 
experiments used isolate virus stocks, originally derived from patient serum samples 
propagated through several passages on Vero cells. ZIKV H/PF/2013 was lethal in Ifnar1-
/- mice, with mice beginning to lose weight at 6 days post-infection (dpi) and all mice 
succumbing by 11 dpi. In contrast, PRVABC59 was attenuated, causing no morbidity or 
mortality.  
  The attenuation of PRVABC59 was unexpected, given its high similarity to 
H/PF/2013 and because other groups have shown the PRVABC59 isolate to be lethal in 
Ifnar1-/- Ifngr1-/- DKO mice (137, 138). To test this, we infected 5- to 6-week-old Ifnar1-/- 
Ifngr1-/- DKO mice, as well as Ifng-/- mice (which do not produce IFN-γ), with 1 x 103 FFU 
of PRVABC59 or H/PF/2013 isolate virus by a subcutaneous route in the footpad and 
evaluated weight loss and lethality (Fig. 3.1 C and D). Ifnar1-/- Ifngr1-/- DKO mice began 
losing weight at 5 dpi, and all mice succumbed to either H/PF/2013 or PRVABC59 virus 
by 10 dpi. These results indicate that despite its attenuation in Ifnar1-/- mice, the 
PRVABC59 isolate can be lethal in a more susceptible mouse model (mice lacking both 
IFN-α/β and IFN-γ signaling). Unsurprisingly, since Ifng-/- mice retain interferon (IFN)-α/β 
signaling, no Ifng-/- mice lost weight or succumbed to either virus, showing that loss of 
IFN-γ signaling is not sufficient to render mice susceptible to ZIKV. To test whether 
PRVABC59 attenuation in Ifnar1-/- mice could be overcome with a higher inoculation dose, 
we infected 5- to 6-week-old Ifnar1-/- mice with 1 x 105 FFU of PRVABC59 isolate virus 
by a subcutaneous route in the footpad and evaluated weight loss and lethality (Fig. 3.1 
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E and F). Mice began losing weight at 5 dpi, but 5 of 7 mice recovered. One mouse began 
losing weight at 5 dpi and continued to lose weight until it succumbed at 11 dpi, while 
another mouse lost weight from 5 to 9 dpi, began to recover, gaining weight until 16 dpi, 
then succumbed at 20 dpi. Thus, even at 100-fold greater inoculation dose, the 
PRVABC59 isolate virus did not cause the ~100% lethality characteristic of the H/PF/2013 
strain in Ifnar1-/- mice. Altogether, these data reveal profoundly different virulence 
phenotypes between ZIKV strain PRVABC59 and H/PF/2013 in Ifnar1-/- mice, despite 
their similar phenotypes in Ifnar1-/- Ifngr1-/- DKO mice. Given the high genetic similarity 
between PRVABC59 and H/PF/2013, we further investigated the viral determinants of 
these distinct virulence phenotypes.  
PRVABC59 isolate contains high frequency variants.  
Although the consensus sequences of PRVABC59 and H/PF/2013 were highly 
similar, isolate viruses typically contain a mixture of genetic variants either present in the 
original patient sample or generated during passage in cell culture. To determine whether 
these two strains included distinct variants compared to their reference genomes, we 
sequenced RNA isolated from concentrated virus stocks using a deep sequencing 
protocol. Most of the variants found in the two virus strains were present at relatively low 
frequencies (<10%), with the variants distributed across the genome. However, the 
PRVABC59 isolate contained 10 variants at >10% frequency, whereas H/PF/2013 
contained 1 variant at >10% frequency, which was not shared between the two viruses. 
(Fig. 3.2A and B).  The PRVABC59 variant present at the highest frequency was a G to 
T mutation at nucleotide 1965, resulting in a Val to Leu substitution at amino acid position 
330 in domain III of the envelope protein. This data is consistent with deep sequencing 
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results of the PRVABC59 strain by other groups, who also identified the V330L 
substitution (137, 138, 209), suggesting that this polymorphism is maintained through 
independent passage of this strain in separate labs. To quantify more accurately the 
frequency of G1965T variation in ZIKV stocks, we next used the Primer ID sequencing 
strategy. Primer ID is a deep sequencing technique that incorporates an eleven 
nucleotide degenerative index into the cDNA synthesis primer, thereby uniquely 
identifying each template sequence and allowing resampled sequencing reads to be 
identified and pooled to create a highly accurate consensus sequence for each template 
(210). Primer ID confirmed an approximately 70% frequency of the G1965T variant in the 
PRVABC59 isolate, whereas no variation was detected at position 1965 of strain 
H/PF/2013 (Fig. 3.2 C and D). To investigate whether this variant was unique to ZIKV 
strain PRVABC59, we performed Primer ID on seven ZIKV strains propagated in either 
Vero or C6/36 cells, including two African lineage strains (Dakar 41662 and Dakar 41671) 
and five Asian-lineage strains (H/PF/2013, PRVABC59, FSS13025, Paraiba_01/2015, 
and Mex-2-81). We also tested two related flaviviruses, Spondweni virus (SPOV) and 
DENV (Table 3.1). The published consensus sequences for all of these viruses encode 
a Val at position 330, except SPOV, which encodes a Leu. We found that only the 
PRVABC59 strain has variation at position 1965, in virus grown in either Vero (69%T) or 
C6/36 cells (72%T). These results indicate the PRVABC59 isolate maintains T/G variation 
at position 1965 of the genome through multiple independent passages, suggesting a 
balanced polymorphism that is not found in other ZIKV strains or in either of two related 
flaviviruses. We next asked whether this variant was responsible for attenuating the 
PRVABC59 isolate in Ifnar1-/- mice. 
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PRVABC59 V330 is lethal in Ifnar1-/- mice, whereas L330 is attenuated.  
To test whether the G/T1965 variant affected ZIKV virulence, we generated 
infectious clones of PRVABC59 or H/PF/2013 with either a G at position 1965 (V330) or 
a T at position 1965 (L330) of the genome (Table 3.2). The PRVABC59 and H/PF/2013 
L330 or V330 viruses replicated equivalently to the isolates in Vero, A549, and C6/36 
cells (Fig. 3.3).   
To evaluate virulence, we infected 5- to 6-week-old Ifnar1-/- mice with 1 x 103 FFU 
of PRVABC59 or H/PF/2013 V330 or L330 clone viruses by a subcutaneous route in the 
footpad and evaluated weight loss and lethality (Fig. 3.4). Mice infected with PRVABC59 
L330 lost weight from 6 to 9 dpi, with only 1 of 7 mice succumbing, whereas mice infected 
with PRVABC59 V330 virus began losing weight at 6 dpi and all mice succumbed by 11 
dpi (Fig. 4A and B). All mice infected with either H/PF/2013 V330 or L330 virus began 
losing weight at 6 dpi and succumbed by 8 dpi (Fig. 3.4C and D). To determine whether 
the PRVABC59 L330 virus could be lethal in a more susceptible mouse model, we 
infected 8-week-old Ifnar1-/- Ifngr1-/- DKO mice with 1 x 103 FFU by a subcutaneous route 
in the footpad. Mice began to lose weight at 4 dpi and all mice succumbed by 10 dpi (Fig 
3.4A and B). These results show that the L330 variant is attenuating on the PRVABC59 
genetic background (with a phenotype similar to the PRVABC59 isolate virus), but did not 
impact virulence on the H/PF/2013 genetic background, altogether implying an epistatic 
effect of L330 on virulence.  
Since the PRVABC59 V330 and L330 viruses produced distinct lethality 
phenotypes in Ifnar1
-/- 
mice, we next compared viral loads in serum and tissues (Fig. 3.5). 
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We infected 5- to 6-week-old Ifnar1-/- mice with 1 x 103 FFU of PRVABC59 V330 or L330 
virus by a subcutaneous route in the footpad and measured viral loads in the serum at 2, 
4, and 6 dpi (Fig. 3.5A) and viral loads in the tissues (spleen, brain, eyes, and testes) at 
6 dpi by reverse transcription-quantitative PCR (qRT-PCR) (Fig. 3.5B-E). Compared to 
the V330 virus, the L330 virus produced similar viral loads at 2 and 4 dpi, but significantly 
lower viral loads at 6 dpi in serum (10-fold reduction). There was no significant difference 
between the PRVABC59 V330 or L330 viral loads in any tissues tested. However, since 
the last PRVABC59 V330 infected mouse succumbed at 11 dpi, viral loads may differ at 
a later time post-infection. To test differences in viral tissue loads between PRVABC59 
V330 and L330 infected mice later after infection, we infected 5- to 6-week-old Ifnar1-/- 
mice with 1x103 FFU of PRVABC59 V330 or L330 virus by a subcutaneous route in the 
footpad and harvested tissues from V330 infected mice when the mice were moribund 
and harvested tissues from L330 infected mice when the last V330 infected mouse was 
harvested (L330-infected mice did not exhibit disease signs). Brain viral loads were 
measured by qRT-PCR (Fig 5F). One PRVABC59 V330 infected mouse was moribund 
and harvested at 8dpi, and all other V330 infected mice were harvested at 9dpi, along 
with all L330 infected mice. At 9dpi, all PRVABC59 L330 mice had significantly lower viral 
loads (1000-fold) in the brain compared to V330 infected mice. Sanger sequencing of 
virus isolated from brains 9dpi confirmed the viruses maintained their original V330 or 
L330 genotype, with no additional mutations throughout E. Altogether, these data show 
that attenuation of the L330 virus corresponds to lower viremia at 6dpi and lower viral 
loads in the brain late in infection, suggesting the L330 virus may be cleared more 
efficiently than V330 virus. 
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Since the PRVABC59 isolate virus is a mix of V330 and L330 virus, we next tested 
whether the attenuated phenotype of the L330 virus was dominant over the virulent 
phenotype of the V330 virus. We infected 5- to 6-week-old Ifnar1-/- mice with a total of 1 
x 103 FFU of PRVABC59 V330:L330 at 1:1, 1:10, 1:100, or 1:1000 ratios of V330:L330 
clone viruses by a subcutaneous route in the footpad and evaluated weight loss and 
lethality (Fig. 3.6). Mice infected with either a 1:1 or 1:10 ratio began losing weight at 5 
days post-infection with all mice succumbing by 10 dpi, similar to mice infected with 
PRVABC59 V330 alone. In contrast, mice infected with a 1:100 or 1:1000 ratio lost weight 
from 6 to 11 dpi with all mice recovering except for one, similar to PRVABC59 L330 alone. 
These data indicate a ratio of 1:100, where the majority of the virus is L330, is able to 
attenuate the V330 virus, consistent with the attenuated phenotype of the PRVABC59 
isolate virus.  
Though the G1965T nucleotide change results in a Val to Leu amino acid 
substitution, the coding change may not be responsible for the difference in virulence 
between PRVABC59 V330 and L330 in Ifnar1-/- mice. Evaulating the nucleotide sequence 
of the PRVABC59 virus with either G1965 or T1965 using a web server for RNA 
secondary structure prediction 
(https://rna.urmc.rochester.edu/RNAstructureWeb/Servers/Fold/Fold.html) showed that 
the nucleotide change may alter the RNA secondary structure at this site (Fig 3.7A). We 
used the same RNA secondary structure prediction server to identify a nucleotide change 
(G1908T) that was predicted to restore the RNA secondary structure of the T1965 virus 
to the G1965 structure (Fig 3.7A). We generated the T1965 + T1908 virus (V034), which 
is predicted to have the same RNA secondary structure as the V330 virus, while encoding 
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a Leu at position 330 (the G1908T mutation also produces an Ala to Pro change at AA 
311 of E). We infected 5- to 6-week-old Ifnar1-/- mice with 1 x 103 FFU of PRVABC59 
L330 or V034 clone viruses by a subcutaneous route in the footpad and evaluated weight 
loss and lethality (Fig. 3.7B and C). Mice infected with V034 did not lose weight and no 
mice succumbed to the virus, whereas mice infected with PRVABC59 L330 lost weight 
from 7 to 11 dpi with all mice recovering, similar to prior experiments. These data suggest 
the predicted RNA secondary structure changes due to the G1965T nucleotide change 
are not responsible for the attenuation of the PRVABC59 L330 virus, although we cannot 
exclude that the Ala to Pro change independently attenuates V034, or that G1965T 
causes RNA structure changes distinct from this predicted structure.  
Nucleotide differences near the 3’ end of the H/PF/2013 genome confer virulence.  
Since the variation at position 330 of the envelope protein only affected virulence 
on the PRVABC59 background, not H/PF/2013, other differences between the two 
viruses must contribute to virulence in Ifnar1-/- mice. The consensus sequences of 
PRVABC59 and H/PF/2013 differ by only 34 nucleotides throughout the entire genome. 
These include 30 silent changes, 1 non-coding change, and 3 coding changes (one in 
capsid (I/T75) and two in the methyltransferase domain of NS5 (V/A37 and V/M60)). To 
test whether any of the three amino acids that differ between the two viruses were 
responsible for their differential lethality in Ifnar1-/- mice, we used site directed 
mutagenesis to generate a PRVABC59 L330 virus (V020) with an amino acid sequence 
identical to H/PF/2013 L330 but maintaining the 31 silent and non-coding nucleotides 
from the PRVABC59 genome (Table 3.2) (Fig. 3.8A). V020 replicated equivalently to 
PRVABC59 L330 in Vero cells (Fig. 3.8B). We infected five- to six-week-old Ifnar1-/- mice 
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with 1 x 103 FFU of PRVABC59 L330 or V020 by a subcutaneous route in the footpad 
and evaluated weight loss and lethality (Fig. 3.8C and D). Mice infected with PRVABC59 
L330 began losing weight from 7 to 10 dpi, with only 1 of 7 mice succumbing to the 
infection, similar to previous experiments (Fig 3.4). Mice infected with V020 did not lose 
weight and no mice succumbed to the infection. These results indicate that the three 
amino acids that differ between the consensus sequences of PRVABC59 and H/PF/2013 
viruses are not responsible for their differential lethality in Ifnar1-/- mice.   
 Since amino acid changes did not explain the observed differences in virulence 
between the PRVABC59-L330 and H/PF/2013-L330 viruses, we next investigated 
whether the remaining 31 nucleotide differences between the two strains were 
responsible. The infectious clone system used to generate PRVABC59 and H/PF/2013 
viruses divides the viral genome over four plasmids (fragments A, B, C, and D) (52, 164). 
The high sequence identity between PRVABC59 and H/PF/2013 preserves the restriction 
sites used to ligate each genomic fragment, making it straightforward to generate 
chimeras of the two strains. We generated chimeric viruses encoding the PRVABC59-
L330 amino acid sequence, but the nucleotide sequence of either PRVABC59 or 
H/PF/2013 and evaluated their virulence in Ifnar1-/- mice (Table 3.2) (Fig. 3.9A).  All 
viruses tested replicated equivalently in Vero cells (Fig. 3.9B). We first tested viruses with 
the 5’ half (fragments A and B) derived from the PRVABC59 nucleotide sequence and 
the 3’ half (fragments C and D) from the H/PF/2013 nucleotide sequence (V024) or vice 
versa (V025) (Fig. 3.9A). We infected 5- to 6-week-old Ifnar1-/- mice with 1 x 103 FFU of 
V024 or V025 virus by a subcutaneous route in the footpad and evaluated weight loss 
and lethality (Fig. 9C and D). Mice infected with V024 began losing weight at 7 dpi and 6 
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of 8 mice succumbed to the virus by 11 dpi, whereas mice infected with V025 did not lose 
weight and no mice succumbed to the virus. Since both viruses encoded the same amino 
acid sequence, these data indicate that nucleotides on the 3’ half of H/PF/2013 genome 
confer virulence in Ifnar1-/- mice. To further define which of these 18 nucleotide 
differences contribute to the virulent phenotype, we generated chimeric viruses still 
encoding the PRVABC59-L330 amino acid sequence but with either the C fragment 
(V026) or D fragment (V027) having the nucleotide sequence of H/PF/2013. The C 
fragment contains 12 nucleotide differences between the two strains, and the D fragment 
contains 6. We infected 5- to 6-week-old Ifnar1-/- mice with 1 x 103 FFU of V026 or V027 
virus by a subcutaneous route in the footpad and evaluated weight loss and lethality (Fig. 
3.7E and F). Mice infected with V026 lost weight from 6 to 12 dpi, with 7 of 9 mice 
recovering, whereas mice infected with V027 began losing weight at 6 dpi and all mice 
succumbed to the virus by 11 dpi. These results implicate one or more of the 6 nucleotide 
differences in the D fragment as virulence determinants for ZIKV H/PF/2013.  
To test if the differential virulence of V026 and V027 corresponded to higher viral 
loads in V027 infected mice, we infected 5- to 6-week-old Ifnar1-/- mice with 1x103 FFU of  
V026 or V027 virus by a subcutaneous route in the footpad and harvested tissues when 
V027 infected mice were moribund (9dpi for all mice). Brain viral loads were measured 
by qRT-PCR (Fig 7G). All V026 infected mice had lower viral loads than V027 infected 
mice at 9dpi, with the exception of one V026 infected mouse, which was the only V026 
infected mouse to show disease signs. These results suggest small differences in CNS 
viral loads can correspond to profound differences in virulence. Sanger sequencing of 
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virus isolated from the brains of infected mice confirmed the viruses maintained the six 
nucleotides that differ in the D fragment, with no additional mutations in the D fragment.  
One of the six nucleotides that differ on the D fragment is in the 3’ UTR, 6 
nucleotides upstream of the first stem loop. This stem loop plays an important role in ZIKV 
virulence, as it inhibits the host 5’-to-3’ exonuclease Xrn1, resulting in a stable 
subgenomic RNA (sfRNA) that facilitates ZIKV replication and pathogenesis by a variety 
of mechanisms (144). To test if this single base change in the 3’ UTR was sufficient to 
confer virulence, we generated a virus (V030) with the single nucleotide change 
(A10392G) on the V020 background (Table 3.2). We infected 5- to 6-week-old Ifnar1-/- 
mice with 1 x 103 FFU of V030 virus by a subcutaneous route in the footpad and evaluated 
weight loss and lethality (Fig 3.9E and F). Mice infected with V030 did not lose any weight 
and no mice succumbed to the virus, indicating that this single nucleotide change is not 
sufficient to confer the virulent phenotype of the V027 virus. These data suggest that one 
of the other five bases or some combination of the six nucleotides that differ between the 
two viruses on the D fragment are responsible for the virulent phenotype of the H/PF/2013 
strain. 
PRVABC59 is not more sensitive to IFN-γ, nor does it induce more IFN-γ than 
H/PF/2013.  
We found that PRVABC59 is not lethal in Ifnar1-/- mice, but equally as lethal as 
H/PF/2013 in Ifnar1-/- Ifngr1-/- DKO mice, suggesting that IFN-γ differentially controls the 
pathogenesis of these two ZIKV strains. We first investigated whether PRVABC59 is more 
sensitive to IFN-γ than is H/PF/2013. We pre-treated Ifnar1-/- mouse embryonic fibroblasts 
(MEF) with 0, 0.5, 1, 5, or 10ng of mouse IFN-γ for 24hrs, washed with PBS, then infected 
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with ZIKV strain H/PF/2013 or PRVABC59 isolate viruses at a MOI of 0.1. Viruses in 
culture supernatants were titrated 24 hours-post infection by focus-forming assay (Fig 
3.10A). We saw a dose-dependent inhibition of both viruses with IFN-γ treatment, 
however there were no significant differences in viral titers between H/PF/2013 and 
PRVABC59 isolate at any IFN-γ concentration. Although we observed no differential 
inhibition in cell culture, we next tested whether the PRVABC59 isolate induces more IFN-
γ than H/PF/2013, possibly leading to attenuation in Ifnar1-/- mice. Five- to six-week-old 
wild-type mice pretreated with 2mg IFNAR1-blocking monoclonal antibody MAR1-5A3 
(134, 199) then inoculated with 1 x 103 FFU of ZIKV strain H/PF/2013 or PRVABC59 and 
serum was collected at 2, 4, 6 and, 8 dpi. We also infected Ifnar1-/- mice and harvested 
serum at 6 dpi. Serum IFN-γ levels were measured by ELISA (Fig 3.10B and C). In wild-
type MAR1 treated mice, IFN-γ levels peaked at 6 dpi, with no significant difference 
between the two viruses. The level of IFN-γ induction was much higher in Ifnar1-/- mice, 
which may be due to increased viral replication compared to MAR1-treated mice, or to 
dysregulated IFN-γ signaling in Ifnar1-/- mice (211). Nonetheless, we did not detect a 
significant difference in IFN-γ levels between the two viruses.  
 Macrophages and dendritic cells (DCs) are two key cell types that regulate innate 
immunity in response to viral infections and are cellular targets of ZIKV infection (212). 
To test if macrophages or DCs are differentially susceptible to ZIKV H/PF/2013 or 
PRVACB59, we measured the growth kinetics of each virus in Ifnar1-/- bone marrow 
derived macrophages (BMDM) or DCs (BMDC). BMDM or BMDC were infected at a MOI 
of 0.01 with ZIKV H/PF/2013 isolate, PRVABC59 isolate, or a Kunjin virus clone as a 
positive control (213–215) and viral supernatants were titered by FFA (Fig 3.11A and B). 
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As expected, Kunjin virus replicated to high titers in both BMDM (8 Log10 FFU/mL at 96 
hpi) and BMDCs (5.5 Log10 FFU/mL). H/PF/2013 replicated to between 3-4 Log10 FFU/mL 
in both cell types, though much slower and to lower levels than Kunjin virus. PRVABC59 
did not replicate in BMDM, but did replicate in BMDC, though to lower viral titers than 
H/PF/2013 (peak titer ~ 2 Log10 FFU/mL). We next tested whether virulence in Ifnar1-/- 
mice corresponded to replication in BMDC. We infected Ifnar1-/- BM DC at a MOI of 0.01 
with H/PF/2013 isolate, PRAVABC59 isolate, H/PF/2013 V330 or L330, PRVABC59 V330 
or L330, V024 or V025 viruses and viral supernatants were titered by FFA (Fig 3.11C). 
There was variable replication among the viruses, plateauing at 48-72 hpi, with 
H/PF/2013 isolate reaching a peak titer of 4.65 Log10 FFU/mL at 48 hpi, followed by V025 
(4.27 Log10 FFU/mL), H/PF/2013 V330 (4.11 Log10 FFU/mL), PRVABC59 V330 (3.42 
Log10 FFU/mL), PRVABC59 L330 (3.42 Log10 FFU/mL), PRVABC59 isolate (3.20 Log10 
FFU/mL),  H/PF/2013 L330 (3.03 Log10 FFU/mL). V024 did not replicate above the limit 
of detection, most likely due to a much lower starting inoculum concentration. Regardless, 
replication in BMDC did not correspond to virulence in Ifnar1-/- mice.  
 Altogether, this work identifies a large and previously unreported difference in 
virulence between two commonly used ZIKV strains. Our data further define the effect of 
a previously reported variant in the PRVABC59 strain. We also identify a novel role for 
non-coding changes as ZIKV virulence determinants, suggesting possible effects on RNA 
properties, such as RNA structure or post-transcriptional modifications. 
3.5 Discussion 
 
The new clinical manifestations associated with ZIKV after its emergence in the 
Western Hemisphere, particularly congenital Zika syndrome, led to a surge in ZIKV 
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research. Many different ZIKV strains have been isolated during the recent outbreaks and 
distributed to research labs around the world (e.g. ~12 contemporary strains available 
from BEI resources and ~20 from the World Reference Center for Emerging Viruses and 
Arboviruses). All contemporary ZIKV strains share high nucleotide identity and minimal 
amino acid differences throughout their genomes and thus have been used largely 
interchangeably to draw conclusions about the pathogenesis of contemporary ZIKV 
strains. However, not all contemporary ZIKV strains share the same pathogenic outcome 
in mice. A ZIKV strain isolated in 2013 from French Polynesia (H/PF/2013) and a strain 
isolated in 2015 from Brazil (Paraiba_01/2015) have been shown to cause 100% and 
80% lethality in Ifnar1-/- mice, respectively (134, 135). In contrast, a ZIKV strain isolated 
in 2010 from Cambodia (FSS13025) was only 20-30% lethal in Stat2-/- or Ifnar1-/- mice, 
and a strain isolated in 2015 from Puerto Rico (PRVABC59) was not lethal in either mouse 
model (136). However, the H/PF/2013, FSS13025, and PRVABC59 strains were 
uniformly lethal in Ifnar1-/- Ifngr1-/- DKO mice (137–140). These data indicate ZIKV strain-
specific contributions to virulence in mice, and highlight that differences in pathogenesis 
may not be evident in highly susceptible models, such as Ifnar1-/- Ifngr1-/- DKO mice. 
Strain characteristics such as virus source (human versus mosquito), disease outcome, 
geographic origin, or year of isolation, do not obviously correlate with pathogenic 
phenotype in mice, though such relationships might be revealed by comparing a larger 
number of strains under identical experimental conditions (136, 166, 216). In this study, 
we describe two distinct genetic determinants of ZIKV strain-specific virulence; notably, 
both phenotypes were evident in Ifnar1-/- mice but masked in Ifnar1-/- Ifngr1-/- DKO mice. 
Our results further define the effect of a previously reported variant in the PRVABC59 
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strain (138), identify a novel role for non-coding changes as ZIKV virulence determinants, 
and highlight that even very closely related virus strains can produce significantly different 
pathogenic phenotypes in common laboratory models.   
 Duggal et al. previously reported variants in the PRVABC59 isolate virus that led 
to attenuated pathogenesis in Ifnar1-/- Ifngr1-/- DKO mice (138). Their deep sequencing 
revealed the presence of a Val to Leu substitution at position 330 of the E protein, as well 
as a Trp to Gly substitution at position 98 of non-structural protein 1 (NS1). These authors 
concluded that the substitutions were tissue culture adaptations, as these variants were 
found at very low levels upon deep sequencing of the original patient sera, and were 
found to increase in frequency over three passages in Vero cells. However, while these 
substitutions increased in frequency with passage, it is not clear whether they are truly 
adaptive. Notably, we did not detect the L330 substitution in the H/PF/2013 strain, even 
though our stock of this strain has been passaged more extensively in Vero cells than the 
PRVABC59 strain, nor was this substitution detected in other ZIKV strains we tested 
(though many of these have less certain passage history). Furthermore, the frequency of 
the V330 and L330 variants remains constant (~70% L330) in independent passages of 
the PRVABC59 strain grown on different cell types (Vero versus C6/36) and by different 
laboratories. The stability of this variation could suggest a balanced polymorphism at this 
site, though the selective advantage of this or why it would be advantageous only on the 
PRVABC59 genetic background is unclear. Our mixed inoculum experiments suggest that 
a ratio of 1:100, where the majority of the virus is L330, is able to attenuate the V330 
virus, consistent with the attenuated phenotype of the PRVABC59 isolate virus. 
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Duggal et al. found that the L330 substitution attenuated the virus in 12- to 16 – 
week - old Ifnar1-/- Ifngr1-/- DKO mice, increasing the mean time to death, and the addition 
of the NS1 G98 substitution further attenuated the virus, highlighting the ability of this 
variant to act epistatically to modulate virulence. We also identified the E L330 and NS1 
G98 variants in our PRVABC59 isolate, which were not present in our H/PF/2013 stock. 
We found that the L330 substitution was sufficient to attenuate the PRVABC59 virus in 
Ifnar1-/- mice (recapitulating the phenotype of the isolate virus), so we did not further 
investigate the NS1 G98 variant.  
ZIKV replicates poorly in mice with intact IFN-αβ signaling, due to an inability to 
antagonize murine STAT2 and STING (131, 132, 217, 218). Thus, mouse pathogenesis 
studies typically use mice deficient in IFN-αβ signaling and both Ifnar1-/- and Ifnar1-/- 
Ifngr1-/- DKO mice are widely used in the field (137, 139, 166, 219–221). However, Ifnar1-
/- Ifngr1-/- DKO mice develop more severe disease and succumb more rapidly to ZIKV 
infection, independent of the inoculation route, compared to Ifnar1-/- mice (139, 222). 
Consistent with the phenotype of the PRVABC59 isolate virus, our PRVABC59-L330 virus 
caused 100% lethality in Ifnar1-/- Ifngr1-/- DKO mice but only 10% lethality in Ifnar1-/- mice. 
We found that the L330 substitution was sufficient to attenuate on the PRVABC59 
genetic backbone (10% lethality with PRVABC59 L330, compared to 100% lethality with 
PRVABC59 V330 in Ifnar1-/- mice). So, it was surprising that this same substitution had 
no effect on the H/PF/2013 backbone (the L330 virus remained 100% lethal). The 
mechanism by which a Val to Leu substitution in domain III of the envelope protein would 
attenuate virulence, and why this would be specific to the PRVABC59 strain remains 
unclear. Apart from V330L variation, the PRVABC59 and H/PF/2013 strains have 
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identical E protein amino acid sequences, so the L330 substitution would be expected to 
have a similar effect on both strains. An alternative explanation is that the distinct 
virulence phenotypes are determined not by the V330L change in the E protein, but by 
the effect of the G1965T nucleotide change on RNA structure or other RNA functions. 
Unfortunately, the codons in this position preclude generating mutants that would 
distinguish the effects of nucleotide and amino acid changes at this site. Our 
compensatory mutant virus data suggest the predicted RNA secondary structure changes 
due to the G1965T nucleotide change are not responsible for the attenuation of the 
PRVABC59 L330 virus, although we cannot exclude that the Ala to Pro change 
independently attenuates V034, or that G1965T causes RNA structure changes distinct 
from this predicted structure.  
Since the L330 substitution was not attenuating on the H/PF/2013 background, 
and the other three amino acids that differ between the two strains did not have an effect 
on virulence, we sought to identify which of the other 31 nucleotide differences between 
the two strains were responsible for the differential lethality. Using chimeric viruses, we 
were able to narrow down the virulence determinant to 6 nucleotide differences in the 3’ 
region of the H/PF/2013 genome (including NS5 and the 3’UTR), though the mechanism 
by which these nucleotide changes modulate virulence remains unclear. Possible 
mechanisms could include effects on RNA structure and/or post-transcriptional 
modifications, though these changes did not obviously disrupt predicted RNA structures 
or predicted m6A modification sites. Though the one nucleotide differences that falls 6 
nucleotides upstream of the first stem loop structure in the 3’ UTR was not sufficient to 
confer virulence, it is plausible that one or more of the other nucleotide changes between 
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PRVABC59 and H/PF/2013 could impact the production, stability, or function of sfRNA 
and thereby modulate ZIKV replication and/or virulence.  
Though PRVABC59 is not lethal in Ifnar1-/- mice, this strain is equally as lethal as 
H/PF/2013 in Ifnar1-/- Ifngr1-/- DKO mice, suggesting that IFN-γ differentially controls the 
pathogenesis of these two ZIKV strains. However, we were not able to detect a significant 
difference in IFN-γ levels between the two viruses in mice, nor a significant difference in 
inhibition by IFN-γ between the two viruses in cell culture.  
Altogether, our work identifies a large and previously unreported difference in 
virulence between two commonly used ZIKV strains, in two widely used mouse models 
of ZIKV pathogenesis (Ifnar1-/- and Ifnar1-/- Ifngr1-/- DKO mice). Our data further describe 
the effect of a previously reported variant in the PRVABC59 strain that appears to be 
attenuating only on the PRVABC59 genetic background. We also identified a novel role 
for non-coding changes as ZIKV virulence determinants, suggesting possible effects on 
RNA structure or post-transcriptional modifications. Our results highlight that even very 
closely related virus strains can produce significantly different pathogenic phenotypes in 
common laboratory models.  
3.6 Materials and methods 
 
Viruses and cells. ZIKV strains H/PF/2013 and PRVABC59 were provided by the U.S. 
Centers for Disease Control and Prevention (172, 173). ZIKV strains Dakar 41662, Dakar 
41671, FSS13025, and Mex-2-81, as well as SPOV, were provided by the World 
Reference Center for Emerging Viruses and Arboviruses (31, 170, 173). Paraiba_01/2015 
was obtained from Dr. Michael Diamond (Washington University in St. Louis) and DENV4 
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(KC963424.1) was obtained from Dr. Aravinda de Silva (UNC) (202, 223). Virus stocks 
were grown in Vero (African green monkey kidney epithelial) cells.  Virus stocks were 
titered on Vero cells by focus-forming assay (FFA) (193).  Vero and A549 cells were 
maintained in Dulbecco’s modified Eagle medium (DMEM) containing 5% heat-
inactivated fetal bovine serum (FBS) and L-glutamine at 37oC with 5% CO2. C6/36 cells 
were maintained in DMEM containing 6% FBS, NEAA, and P/S at 32oC with 5% CO2. 
Macrophages and dendritic cells were generated after cell isolation from the bone marrow 
of Ifnar1-/- mice and culturing for 7 days either in the presence of 40 ng/ml macrophage 
colony-stimulating factor (MCSF; BioLegend) to generate macrophages or with 20 ng/ml 
granulocyte-macrophage CSF (GM-CSF; BioLegend) and 20 ng/ml interleukin-4 (IL-4; 
BioLegend) to generate dendritic cells. For multi-step growth analysis, cells were infected 
at a multiplicity of infection of 0.01 and incubated at 37oC or 32oC with 5% CO2 for one 
hour. Then, inoculum was aspirated and cells were washed with PBS and media was 
replenished. Samples of infected cell culture supernatant were collected at 4, 24, 48, 72, 
and 96 hrs post-infection and stored at -80oC for virus titration. Virus quantification was 
performed by FFA on Vero cells. Duplicates of serial 10-fold dilutions of virus in viral 
growth medium (DMEM containing 2% FBS and 20 mM HEPES) were applied to Vero 
cells in 96-well plates and incubated as described above for 1 hr. Following virus 
adsorption, the monolayers were overlaid with 1% methylcellulose in minimum essential 
medium Eagle (MEM). Infected cell foci were detected 42-46 hrs after infection. Following 
fixation with 2% paraformaldehyde for 1 hr at room temperate, plates were incubated with 
500 ng/ml of flavivirus cross-reactive mouse MAb E60 (194) for 2 hr at room temperature 
or overnight at 4oC. After incubation at room temperate for 2 hr with a 1:5,000 dilution of 
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horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sigma), foci were 
detected by addition of TrueBlue substrate (KPL). Foci were quantified with a CTL 
Immunospot analyzer.  
ZIKV infectious clone mutagenesis. We used previously described infectious clones of 
ZIKV stains H/PF/2013 or PRVABC59, generated using a quadripartite infectious clone 
system (164)(52). Due to the high sequence identity between H/PF/2013 and 
PRVABC59, the same naturally occurring class IIG nonpalindromic restriction 
endonuclease sites within the full-length genome were used for both infectious clones, 
allowing us to swap fragments between the two strains to generate chimeric viruses. PCR 
site-directed mutagenesis was used to introduce mutations to H/PF/2013 or PRVABC59 
plasmids. The resulting purified plasmids were digested, ligated, in vitro transcribed, and 
electroporated into Vero or C6/36 cells as previously described (195). Supernatants from 
electroporated Vero or C6/36 cells were harvested after 6 to 7 days and passaged once 
on Vero cells to generate virus stocks. Virus stocks were titrated by FFA on Vero cells. 
Restriction enzymes and Phusion High Fidelity PCR kit were obtained from New England 
BioLabs. SuperScript III First Strand Synthesis kit was obtained from Invitrogen. 
Oligonucleotide primers and probes for DNA amplification, qRT-PCR, and sequencing 
primers were obtained from Sigma and IDT. The mMachine T7 Ultra transcription kit was 
obtained from Ambion. Anti-flavivirus monoclonal antibodies E60 and 4G2 were produced 
by the UNC Protein Expression and Purification Core Facility (194, 197). Secondary 
antibodies were obtained from Sigma.   
Mouse Experiments. Animal husbandry and experiments were performed under the 
approval of the University of North Carolina at Chapel Hill Institutional Animal Care and 
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Use Committee. Five - to six-week old, or 8-week-old, male and female Ifnar1-/-, Ifnar1-/- 
Ifngr1-/- DKO, or Ifng-/- mice on a C57BL/6 background were used. Mice were inoculated 
with 1 x 103 or 1 x 105 FFU of ZIKV in a volume of 50μl by a subcutaneous route in the 
footpad. Survival and weight loss were monitored for 14 or 21 days. Animals that lost 
≥30% of their starting weight or that exhibited severe disease signs were euthanized. 
Measurement of Viral Burden. ZIKV-infected mice were sacrificed at 6 dpi and perfused 
with 20 ml of PBS. Spleen, kidney, testes, brain, and eyes were harvested and 
homogenized with zirconia beads (BioSpec) in a MagNA Lyser instrument (Roche Life 
Science) in 500μl (eyes) or 1ml (all other tissues) of buffer RLT (Qiagen). Blood was 
collected at 2 and 4 dpi by submandibular bleed with a 5mm Goldenrod lancet and by 
cardiac puncture at 6 dpi. Blood was collected in serum separator tubes (BD) and serum 
was separated by centrifugation at 8000rpm for 5 min. Tissues and serum from infected 
animals were stored at -80oC until virus titration. Tissue samples and serum from ZIKV-
infected mice were extracted with the RNeasy Mini Kit (tissues) or Viral RNA Mini Kit 
(serum) (Qiagen). ZIKV RNA levels were determined by TaqMan one-step qRT-PCR on 
a CFX96 Touch Real-Time PCR Detection System (BioRad) using standard cycling 
conditions. Viral burden is expressed as genome copies per ml on a Log10 scale after 
comparison with a standard curve produced using serial 100-fold dilutions of ZIKV A 
plasmid. A previously published primer set was used to detect ZIKV RNA: forward, 
CCGCTGCCCAACACAAG; reverse, CCACTAACGTTCTTTTGCAGACAT; probe, /56-
FAM/AGCCTACCT/ZEN/TGA CAAGCAATCAGACACTCAA/3IABkFQ/ (Integrated DNA 
Technologies) (52, 200).  
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IFN-γ ELISA. Blood was collected from ZIKV-infected mice at 2, 4, 6, or 8 dpi by 
submandibular bleed with a 5mm Goldenrod lancet. Blood was collected in serum 
separator tubes (BD) and serum was separated by centrifugation at 8000rpm for 5 min.  
A mouse IFN-y Uncoated ELISA was performed according to the manufacturers protocol 
(Invitrogen) as follows. A Corning Costar 96-well plate was coated with 100μl per well of 
capture Ab in Coating buffer and the plate was incubated overnight at 4oC. The wells were 
washed three times with PBS and blot dried. Wells were blocked with 200μl per well 
ELISA/ELISPOT diluent and incubated at room temperature for one hour. Wells were 
aspirated and washed once with PBS. A standard curve was prepared by performing 2-
fold serial dilutions of provided mouse IFN gamma with a starting concentration of 1000 
pg/mL.  50μl of serum was added to the appropriate wells and the plate was sealed and 
incubated overnight at 4oC.  Wells were aspirated and washed three times with PBS. 
Next, 100μl of detection Ab was added to each well and the plate was incubated at room 
temperature for one hour. Wells were aspirated and washed three times with PBS. Then, 
100μl Avidin-HRP was added to each well and the plate was incubated at room 
temperature for 30 minutes. Wells were aspirated and washed three times with PBS. 
Then, 100μl of 1X TMB solution was added to each well and incubated at room 
temperature for 15 minutes. Finally, 50μl Stop Solution was added to each well and the 
plate was read at 450nm on an Epoch spectrophotometer (BioTeK). 
Deep sequencing. Viruses were grown on Vero cells and virions were concentrated over 
a 20% sucrose cushion by ultracentrifugation and full-length virion RNA was extracted 
using TRIzol (Ambion) following manufacturer’s protocol. PRVABC59 RNA was 
submitted to the UNC Chapel Hill Vironomics Core for library construction and sequencing 
85 
 
on an Ion S5 (ThermoFisher Scientific).  H/PF/2013 cDNA was made using extracted full-
length virion RNA using Random Primer 9 (NEB) and SuperScript II and the second 
strand of the cDNA was synthesized using NEBNext Ultra II Non-Directional RNA Second 
Strand Synthesis Module (NEB) following the manufacturer’s suggested protocol.  
Libraries were constructed from this double stranded cDNA using Nextera XT DNA 
Library Prep kit following manufactures suggested protocol, quantified using a 4200 
TapeStation System (Agilent Technologies), and quantified using Qubit dsDNA HS Assay 
Kit (ThermoFisher Scientific).  Libraries were sequenced on a MiSeq Desktop Sequencer 
(Illumina).   
Primer ID. Viral RNA was extracted using a QIAamp viral RNA mini kit (Qiagen). Primer 
ID sequencing libraries were constructed as previously described (224). In brief, we used 
the SuperScript III kit (ThermoFisher) with cDNA primers containing a block of degenerate 
nucleotides (the Primer ID) to synthesize cDNA. After bead purification of the cDNA 
product using RNAClean XP (Beckman), two rounds of PCR were performed to 
incorporate MiSeq sequencing adaptors. Amplified products were purified, pooled, and 
sequenced using Illumina MiSeq 300 bp paired-end sequencing. A detailed protocol can 
be accessed at https://www.protocols.io/view/primer-id-miseq-library-prep-useewbe. We used 
the Illumina bcl2fastq pipeline for the initial data processing and the TCS pipeline 
(https://github.com/SwanstromLab/PID) to construct template consensus sequences.  
Data Analysis. All data were analyzed with GraphPad Prism software. Kaplan-Meier 
survival curves were analyzed by the log rank test, and weight losses were compared 
using two-way ANOVA. For viral burden analysis, the log-transformed titers were 
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Figure 3.1. PRVABC59 is attenuated in Ifnar1-/- mice. Five- to six-week-old Ifnar1-/- , 
Ifnar1-/-  Ifngr-/- , or Ifng-/- mice were inoculated with 1 x 103 (A to D) or 1 x 105 (E and F) 
FFU of ZIKV strain PRVABC59 or H/PF/2013 isolate viruses by a subcutaneous route. 
(A, C, and E) Mice were weighed daily for 14 days, and weights are expressed as 
percentages of body weight prior to infection. Results shown are the mean values ± 
SEM of the indicated number of mice from one (E and F) or two independent 






Figure 3.2. PRVABC59 isolate contains high frequency variants. A and B: Deep 
sequencing was performed on ZIKV strain PRVABC59 and H/PF/2013. The cut-off for 
single nucleotide polymorphisms was set at a depth ≥ 10 reads and a mutation rate ≥ 3% 
(black dashed line). The gray dashed line indicates 10% mutation rate. C and D: Primer 
ID was performed on ZIKV strains PRVABC59 and H/PF/2013 for the indicated 483 











Figure 3.3. V330L substitution does not impact ZIKV replication in cell culture.  Vero 
(A and D), A549 (B and E), or C6/36 (C and F) cells were infected at a MOI of 0.01 with 
ZIKV PRVABC59 or H/PF/2013 isolate, V330 clone, or L330 clone virus. Viruses in culture 
supernatants were titrated by focus-forming assay. Data shown are the mean values ± 







Figure 3.4. V330L substitution is attenuating on a PRVABC59 but not H/PF/2013 
background in Ifnar1-/- mice. 5-to-6-week-old Ifnar1-/- or 8-week-old Ifnar1-/-  Ifngr1-/- 
DKO mice were inoculated with 1x103 FFU ZIKV strain PRVABC59 or H/PF/2013 V330 
or L330 viruses by a subcutaneous route. (A and C) Mice were weighed daily for 14 days. 
Weights are expressed as percent of body weight prior to infection and censored once 
one mouse in a group died. (B and D) Lethality was monitored for 21 days. Results shown 
are the mean ± SEM of 11-14 Ifnar1-/- mice (PRVABC59 V330 and L330), 9 Ifnar1-/- mice 







Figure 3.5. PRVABC59 330 variants produce similar viral loads. Five- to six-week-old 
Ifnar1
-/- 
mice were inoculated with 1 x 10
3
 FFU of ZIKV strain PRVABC59 V330 or L330 
virus by a subcutaneous route in the footpad. (A) Blood was collected at 2, 4, and 6 days 
after infection, and ZIKV RNA in serum was measured by qRT-PCR. (B to F) Mice were 
euthanized 6 or 9 days after infection, perfused, and tissues were harvested. ZIKV RNA 
in tissue was measured by qRT-PCR. ***, P< 0.001 (unpaired 2-tailed t test). Results 




Figure 3.6. A 1:100 ratio of V330 to L330 attenuates V330 lethality. Five- to six-
week-old Ifnar1-/- mice were inoculated with 1 x 103 FFU of ZIKV strain PRVABC59 
V330, L330, or the indicated ratio of V330:L330 virus by a subcutaneous route. A. Mice 
were weighed daily, and weights are expressed as percentages of body weight prior to 
infection. B. Lethality was monitored for 14 days. Results shown are the mean values ± 
SEM of 4-8 Ifnar1-/- mice per virus from two or three independent experiments. Lethality 




Figure 3.7. RNA secondary structure does not confer differential lethality between 
PRVABC59 G1965T.  (A) Predicted RNA secondary structure of PRVABC59 V330 
(G1965), L330 G1965T, and a compensatory mutation to restore the V330 RNA 
structure (G10908T) while maintaining T1965. (B and C) Five- to six-week-old Ifnar1-/- 
mice were inoculated with 1 x 103 FFU of ZIKV strain PRVABC59 L330, or PRVABC59 
G1908T (V034) virus by a subcutaneous route. Mice were weighed daily, and weights 
are expressed as percentages of body weight prior to infection. Lethality was monitored 
for 14 days. Results shown are the mean values ± SEM of 4 Ifnar1-/- mice per virus in 





Figure 3.8. Three amino acids that differ between H/PF/2013 and PRVABC59 do not 
confer lethality. (A) Schematic of PRVABC59 L330 and V020 genomes depicts the 
introduction of 3 H/PF/2013 amino acids (stars); small circles indicate nucleotide 
differences between PRVABC59 and H/PF/2013. (B) Vero cells were infected at an MOI 
of 0.01 with ZIKV PRVABC59 L330 or V020. Viruses in culture supernatants were titrated 
by focus-forming assay. Data shown are the mean ± SEM of 9 samples from 3 
independent experiments.  (C and D) Five-to six-week-old Ifnar1
-/-  
mice were inoculated 
with 1 x 10
3
 FFU ZIKV strain PRVABC59 L330 or V020 virus by a subcutaneous route. 
Mice were weighed daily for 14 days, and weights are expressed as percentages of body 
weight prior to infection and censored once one mouse in a group died. Results shown 
are the mean values ± SEM of 7 mice for PRVABC59 L330 and 11 mice for V020 from 




Figure 3.9. H/PF/2013 3’ end confers lethality in mice. (A) Schematic of PRVABC59 and 
H/PF/2013 chimeric viruses (V024-V027) and a single 3’ UTR nucleotide change (V031). (B) 
Vero cells were infected at an MOI of 0.01 with ZIKV H/PF/2013 L330, V024, V025, V026, 
V027, or V030. Viruses in culture supernatants were titrated by focus-forming assay. Data 
shown are the mean ± SEM of 9 samples from 3 independent experiments. Five-to six-week-
old Ifnar1-/-  mice were inoculated with 1x103 FFU ZIKV V024 or V025 (C and D) and V026, 
V027, or V030 (E and F) by a subcutaneous route. (C-F) Mice were weighed daily for 21 
days and weights are expressed as percentages of body weight prior to infection. Results 
shown are the mean values ± SEM of the indicated number of Ifnar1-/- mice for each virus 
from three independent experiments. Lethality was monitored for 21 days. (G) Five-to six-
week-old Ifnar1-/-  mice were inoculated with 1x103 FFU ZIKV V026 or V027 by subcutaneous 
route. Mice were euthanized 9 days after infection, perfused, and tissues were harvested. 






Figure 3.10.  No difference between H/PF/2013 and PRVABC59 inhibition by 
IFN-γ in tissue culture or in IFN-γ levels in sera of infected mice. (A) Ifnar1
-/- 
mouse embryonic fibroblasts were pre-treated with 0, 0.5, 1, 5, or 10ng of mouse 
IFN-γ for 24hrs, washed with PBS, and infected with ZIKV strain H/PF/2013 or 
PRVABC59  at a MOI of 0.1. Viruses in culture supernatants were titrated 24 hours-
post infection by focus-forming assay. (B and C) Five- to six-week-old WT mice 
pretreated with 2mg IFNAR1-blocking MAb MAR1 (B) or Ifnar1
-/- 
mice (C) were 
inoculated with 1 x 10
3
 FFU of ZIKV strain H/PF/2013 or PRVABC59 and serum was 
collected at the indicated days post-infection. Serum IFN-γ levels were measured by 
ELISA. Data shown are the mean values ± standard errors of the means (SEM) of 4 
samples from 2 independent experiments for (A), three independent experiments for 




Figure 3.11. PRVABC59 isolate is attenuated in mouse immune cells. (A and B) 
Ifnar1
-/- 
bone marrow derived macrophages (BMDM) or bone marrow derived 
dendritic cells (BMDC) were infected at an MOI of 0.01 with ZIKV H/PF/2013 isolate, 
PRVABC59 isolate, or WNV Kunjin. (C)  Ifnar1
-/-
 BMDC were infected at an MOI of 
0.01 with H/PF/2013 isolate, PRAVABC59 isolate, H/PF/2013 V330 or L330, 
PRVABC59 V330 or L330, V024 or V025. Virulent or attenuated viruses in Ifnar1
-/ 
mice are indicated. Viruses in culture supernatants were titrated by focus-forming 






Table 3.1. Variation at position 1965 of the genome is unique to 
ZIKV PRVABC59. Viruses grown in Vero or C6/36 cells were deep 
sequenced by Primer ID and percent nucleotide variation is shown. The 





Table 3.2. ZIKV infectious clones and mutants. ZIKV clones, mutants, and chimeras 
were generated from PRVABC59 (PRV) or H/PF/2013 (PF) strains using a 
quadripartite infectious clone system. The ZIKV strain origin of each backbone 
fragment (A-D) and any nucleotide changes and the resulting amino acid substitution 
are indicated. Amino acid numbering is for individual proteins (C, E, or NS5), nucleotide 
numbering for the complete genome. I75T is in C, V330L is in E, and V2611A and 
V2634M are in NS5.  
1
Amino acid numbering for individual proteins (C, E, or NS5) 
2






CHAPTER 4 – ZIKV XRRNA FACILITATE REPLICATION 
 
4.1 Summary 
 Flaviviruses produce a 300–500–base long non-coding RNA, termed 
subgenomic flavivirus RNA (sfRNA), via structures in the 3’ untranslated region (UTR) 
that stall the cellular 5’-3’ exonuclease Xrn1. The generation of sfRNA by these Xrn1 
resistant RNAs (xrRNA), facilitates flavivirus replication and pathogenesis by multiple 
mechanisms. Characterization of Zika virus (ZIKV) xrRNA by nuclear magnetic 
resonance (NMR) spectroscopy revealed a distinct thermodynamic fingerprint for 
indexing Xrn1 resistance. In this study we tested whether mutations that are predicted 
to destabilize the xrRNA inhibit ZIKV replication. Overall, our data suggest xrRNA 
activity is essential for ZIKV replication but xrRNA1 and xrRNA2 are largely redundant. 
4.2 Importance 
 The molecular mechanisms that facilitate flavivirus transmission by mosquitoes 
remain unclear. Here, we demonstrate that highly structured regions in the 3’ UTR that 
cause the host 5’-3’ exonuclease Xrn1 to stall are essential for ZIKV replication.  
4.3 Introduction 
Mosquito-borne flaviviruses, such as Zika virus (ZIKV), dengue virus (DENV), 
West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV), 
as well as tick-borne flaviviruses, such as tick-borne encephalitis virus (TBEV) are 
important endemic and emerging human pathogens that can cause hemorrhagic fever, 
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encephalitis, and birth defects (1, 2, 225, 226). The geographic areas where flaviviruses 
are transmitted is growing, as climate change and global commerce expands the range 
of vector mosquitoes and ticks. The ability of flaviviruses to be transmitted by 
mosquitoes and ticks is crucial to their emergence and spread, but the cellular 
mechanisms that dictate flavivirus host range are not fully understood. Flaviviruses have 
a positive-sense single stranded RNA genome that encodes a single open reading 
frame flanked by 5’ and 3’ untranslated regions (UTR). Located at the 5’ end of the 3’ 
UTR are two highly structured RNA motifs called Xrn1 resistant RNAs (xrRNA1 and 
xrRNA2). These xrRNAs cause the host 5’-3’ exonuclease Xrn1 to stall, resulting in 
stable RNA degradation products known as subgenomic flavivirus RNAs (sfRNAs). 
These stable sfRNA have been implicated in the induction of pathogenicity in mice and 
cytopathicity in cell culture, evasion of the type I/II IFN response, decreased mRNA 
turnover, enhanced virus replication in mammalian cells, and the infection and 
subsequent transmission by mosquito vectors (145–152). High-resolution X-ray 
structures of mosquito-borne flavivirus xrRNAs have identified a core conformation that 
encapsulates the 5’-end of xrRNAs, yet also display variable long-range interactions for 
pseudoknot formation (227, 228). Our collaborators in the UNC Department of 
Biochemistry and Biophysics, Rhese Thompson and Dr. Qi Zhang, used nuclear 
magnetic resonance (NMR) spectroscopy and hydrogen-deuterium-exchange to 
characterize structural dynamics of ZIKV xrRNA. These thermodynamic fingerprints 
show that ZIKV xrRNA is orders of magnitude more stable than other RNA structures 
previously reported, with stability controlled by long-range pseudoknot interactions. The 
unprecedented stability of ZIKV xrRNA was only revealed by NMR and would not be 
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evident by other biochemical or biophysical approaches. NMR characterization of ZIKV 
xrRNA reveals a distinct thermodynamic fingerprint for indexing Xrn1 resistance. 
Although these methods identified xrRNA1 and xrRNA2 as highly stable RNA 
structures, they could not ascertain whether these structures were important for viral 
replication, or whether the two structures served independent functions. These xrRNAs 
may be redundant, meaning that xrRNA2 serves as a backup if xrRNA1 is degraded. 
On the other hand, they may both be important and serve distinct roles in flavivirus 
replication.  
In this study, we evaluated the effects of xrRNA stability on ZIKV replication in 
tissue culture. We used site-directed mutagenesis to introduce mutations that are 
predicted to destabilize xrRNA1 or xrRNA2 in a previously described infectious clone of 
the Asian-lineage ZIKV strain H/PF/2013 (164).  We show that ZIKV xrRNA mutants 
replicate equivalently in two mosquito cell lines, C6/36 and U4.4, but are slightly 
attenuated in mammalian Vero cells. Accordingly, the xrRNA mutants produced a 
significantly smaller infectious foci by focus-forming assay (FFA), suggesting a small 
difference in replication and/or impaired cell-to-cell spread. Interestingly, we were 
unable to recover infectious clones with mutations in both xrRNA1 and xrRNA2. 
Competition assays showed mutants with destabilized xrRNA1 replicate equivalently to 
WT virus through 72 hours post-infection (hpi). However, a destabilized xrRNA1 mutant 
out-competed an xrRNA2 mutant. Overall, our data suggest xrRNA activity is essential 




Destabilized xrRNA mutants replicate equivalently to WT 
 
To test  whether mutations that destabilize xrRNA1 or xrRNA2 affect replication, 
we used PCR site-directed mutagenesis to introduce mutations predicted to destabilize 
xrRNA1 or xrRNA2 in a previously described infectious clone of the Asian-lineage ZIKV 
strain H/PF/2013 (164). We generated two xrRNA1 mutants: a CCCC>AAAA (V028) or 
a CCCC>CTCT (V029) (Fig 4.1B and C).  Both mutations are predicted to disrupt the 
pseudoknot interaction stabilizing the xrRNA structure, with V028 being less stable than 
V029. To generate the xrRNA2 mutant we introduced a single base change (C>G) at 
position 10,946 of the genome, which is predicted to destabilize xrRNA2 (V031) (Fig 
4.1D). We also attempted to generate double mutants, combining the xrRNA2 mutation 
of V031 with either of the two xrRNA1 mutations (from V028 or V029), but were unable 
to recover these viruses after 6 electroporations into Vero or C6/36 cells. Our ability to 
rescue xrRNA1 and xrRNA2 mutants individually but not in combination suggests a 
redundant essential function for these two xrRNA structures in replication of ZIKV. We 
compared replication of WT, V028, V029, and V031 mutants in Vero cells and mosquito 
cells (Fig 4.2). C6/36 and U4.4 cells both are derived from Aedes albopictus, but C6/36 
cells have a mutation in Dicer2 that ablates the RNAi-mediated antiviral response and 
renders these cells highly permissive to viral infection (229). Since a known function of 
flavivirus sfRNA is antagonizing Dicer2 and the RNAi response in mosquitoes, we 
expected xrRNA mutants to be attenuated in U4.4 cells, which retain a functional RNAi 
response, but not compromised in C6/36 or Vero cells. However, V028, V029, and V031 
mutants replicated equivalently to WT virus in C6/36 and U4.4 cells in multi-step growth 
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curves. Interestingly, in Vero cells, V028 and V031 replicated to statistically significant 
lower viral titers at 48 and 72 hpi compared to WT virus. V029 replicated to lower levels 
than WT, but the difference was not statistically significant.  
xrRNA mutants produce smaller infectious foci in Vero cells 
 In accordance with our Vero cell growth curve data, all xrRNA mutants produced 
significantly smaller foci by focus-forming assay (FFA) on Vero cells (Fig 4.3A). The 
wild-type virus produced foci ~3.2 x 104 µm2, whereas V028, V029, and V031 produced 
foci ~9 x 103 µm2  (Fig 4.3B). These data suggest that even though a similar amount of 
virus is being released into the supernatants (Fig 4.2), the xrRNA mutants may have a 
modest replication defect not evident in the supernatant titers measured on a log10 
scale. We also measured whether there was a difference in genome to FFU ratio 
between the xrRNA mutants and wild-type virus. WT virus had a ratio of 805, V028 a 
ratio of 1527, V029 a ratio of 1665, and V031 a ratio of 7638 (Fig 3C). These data 
suggest the WT virus is more efficiently packaged, followed by V028, V029, and then 
V031.We next considered whether a competition experiment might reveal a replication 
impairment not evident in the growth curves. We tested whether wild-type virus would 
out-compete xrRNA1 mutants (V028 and V029) and whether there is a fitness 
difference between destabilized xrRNA1 (V028) and destabilized xrRNA2 (V031) (Fig 
4.4). We infected U4.4 cells at a total MOI of 0.1 with a 1:1 ratio of WT:V028, WT:V029, 
or V028:V031 (Fig 4.4A) and assessed the relative proportions of each virus by 
inspecting chromatograms from Sanger sequencing of the inoculum and of culture 
supernatants at 72hpi. The proportions of WT:V028 and WT:V029 remained similar at 
72 hpi, compared to the inoculum, suggesting that the destabilization of xrRNA1 did not 
105 
 
reduce viral fitness. We found similar results upon testing an inoculum with a 10:1 ratio 
of V028:WT or V029:WT (Fig 4.4B). In contrast, a destabilized xrRNA1 mutant (V028) 
out-competed an xrRNA2 mutant (V031), as the V028 genotype dominated at 72 hpi, 
whether at a starting ratio of 1:1 or 10:1 V031:V028.  
4.5 Discussion 
 The molecular determinants of arbovirus transmission by mosquitoes are not fully 
understood, and few interactions between arboviruses and their vectors have been 
described in molecular detail. Flaviviruses produce a 300–500–base long stable RNA 
degradation product (sfRNA) that results from the stalling of the host 5’-3’ exonuclease 
Xrn1 on RNA structures (xrRNAs) in the 3’UTR. sfRNAs facilitate flavivirus replication 
and pathogenesis by multiple mechanisms (144, 230). Here, we investigated the effect 
of mutations predicted to destabilize two structures in the ZIKV 3’UTR, xrRNA1 and 
xrRNA2. We found that destabilizing either xrRNA1 or xrRNA2 did not significantly 
affect ZIKV replication as measured in a multi-step growth curve in C6/36 and U4.4 
cells, but may cause a modest replication defect in Vero cells as seen by a significantly 
smaller foci by FFA. The inability to recover double mutant viruses with mutations in 
both xrRNA1 and xrRNA2 suggests that xrRNA activity is essential for ZIKV replication 
and that these two structures serve largely redundant functions. In a multi-step growth 
curve, all three xrRNA mutants replicated equivalently. However, a competition assay 
revealed that a mutant with a severely destabilized xrRNA1 (V028) was more fit than a 
mutant destabilizing xrRNA2 (V031), suggesting that the functions of xrRNA1 and 
xrRNA2 are not identical and that xrRNA2 activity may be more important than xrRNA1 
activity for ZIKV replication. Future studies will assess additional xrRNA1 and xrRNA2 
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mutants with variable stability (as determined by NMR thermodynamic fingerprint 
analysis), to titrate the relative activity of xrRNA1 and xrRNA2 and thereby better 
determine their distinct contributions to flavivirus replication. Future studies also will 
measure sfRNA levels during infection to confirm that xrRNA destabilizing mutations 
have the expected effect on sfRNA production. While some 3’ UTR RNA structures are 
conserved, there is variation among flaviviruses in the set of xrRNAs present in the 
3’UTR and their thermodynamic fingerprints. Furthermore, tick-borne flaviviruses are 
predicted to have distinct xrRNA structures, though there are no experimentally 
validated xrRNA structures for tick-borne flaviviruses. Altogether, the combination of 
new methods for determining thermodynamic fingerprints that predict xrRNA stability 
along with molecular virology approaches to assess xrRNA function creates an 
opportunity for new discoveries in the molecular mechanisms that mediate flavivirus 
replication, transmission, and pathogenesis. 
4.6 Materials and methods  
 
Cells and viruses. Vero, C6/36, and U4.4 cells were maintained in Dulbecco’s 
modified Eagle medium (DMEM) containing 5% heat-inactivated fetal bovine serum 
(FBS) and L-glutamine at 37oC with 5% CO2 for Vero cells or 28oC without CO2 for 
C6/36 and U4.4 cells. Virus stocks were grown in Vero (African green monkey kidney 
epithelial) cells.  Virus stocks were titered on Vero cells by focus-forming assay (FFA) 
(193). For multi-step growth analysis, cells were infected at a MOI of 0.1 and incubated 
at 37oC with 5% CO2 (Vero cells) or 28oC without CO2 (C6/36 and U4.4 cells). Samples 
of infected cell culture supernatant were collected at 4, 24, 48 and 72 hpi and stored at -
80oC for virus titration. Virus quantification was performed by FFA on Vero cells. 
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Duplicates of serial 10-fold dilutions of virus in viral growth medium (DMEM containing 
2% FBS and 20 mM HEPES) were applied to Vero cells in 96-well plates and incubated 
at 37oC with 5% CO2 for 1 hr. Cells were then overlaid with 1% methylcellulose in 
minimum essential medium Eagle (MEM). Infected cell foci were detected 42-46 hpi. 
Following fixation with 2% paraformaldehyde for 1 hr at room temperature, plates were 
incubated with 500 ng/ml of flavivirus cross-reactive mouse MAb E60 (194) for 2 hr at 
room temperature or overnight at 4oC. After incubation at room temperate for 2 hr with a 
1:5,000 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG 
(Sigma), foci were detected by addition of TrueBlue substrate (KPL). Foci were 
quantified with a CTL Immunospot instrument.  
ZIKV infectious clone design and mutagenesis. We generated xrRNA mutants 
in a previously described infectious clone of ZIKV strain H/PF/2013 (164). Site-directed 
mutagenesis was used to introduce the mutations CCCC>AAAA at position 10450-10453 
of the genome (V028), CCCC>CTCT at position 10451 and 10453 of the genome (V029), 
and C10496G (V031) in the 3’ UTR to destabilize xrRNA secondary structures. 
Supernatants from electroporated C6/36 cells were harvested after 6 to 7 days and 
passaged once on Vero cells to generate virus stocks. Virus stocks were titered by FFA 
on Vero cells. Restriction enzymes and Phusion High Fidelity PCR kit were obtained from 
New England BioLabs. SuperScript III First Strand Synthesis kit was obtained from 
Invitrogen. Oligonucleotide primers and probes for DNA amplification, qRT-PCR, and 
sequencing were obtained from Sigma and IDT. The mMachine T7 Ultra transcription kit 
was obtained from Ambion. 
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Competition assay. U4.4 cells were plated at 1 x 106 cells/well in 6-well plates. 
Cells were inoculated with a 1:1 or 10:1 mixture of viruses at a total MOI of 0.1 in 
triplicate wells. Viral supernatants were harvested at 72 hours post-infection. Viral RNA 
was extracted from all samples using Viral RNA mini kit (Qiagen), followed by cDNA 
synthesis with SuperScript III First Strand Synthesis kit (Invitrogen), then PCR to amplify 
the 3’ UTR. PCR products were run on a 1% agarose gel and DNA bands were 
extracted using a DNA gel extraction kit (Zymo). Amplicons were sequenced by Sanger 








Figure 4.1. ZIKV xrRNA1 and xrRNA2 and destabilizing mutations. (A) WT  
xrRNA1 and xrRNA2 structures (B) Mutations (CCCC>AAAA) made to generate 
V028, which severely destabilizes the xrRNA1 pseudoknot (C) mutations 
(CCCC>CTCT) made to generate V029, which modestly destabilizes the xrRNA1 
pseudoknot and (D) mutation (C10496G) made to generate V031, which 
destabilizes xrRNA2. Mutations are highlighted with red circles.  
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Figure 4.2. xrRNA mutants replicate similarly to WT virus in multi-step growth 
curves.  Vero (A), C6/36 (B), or U4.4 (C) cells were infected at a MOI of 0.1 with 
ZIKV H/PF/2013 WT clone, V028, V029, or V031. Viruses in culture supernatants 
were titered by focus-forming assay. Data shown are the mean values ± standard 
errors of the means (SEM) of 12 samples from 4 independent experiments for WT, 




Figure 4.3. xrRNA mutants produce smaller infectious foci.  (A) Vero cells 
infected with the indicated viruses were fixed 44hpi and infected cell foci visualized 
by antibody staining. (B) Area of WT, V028, V029, or V031 infectious foci. (C) 
Genome:PFU ratio for each virus. Data shown are the mean values ± standard 











Figure 4.4. xrRNA mutants retain fitness in competition assays. U4.4 cells 
were infected with the indicated pair of viruses at a 1:1 (A) or 10:1 (B) ratio at a 
total MOI of 0.1. Input virus and 72hpi supernatant virus were analyzed by Sanger 
sequencing, with chromatograms indicating the mixture of sequences present. The 
experiments were performed in triplicate, and one representative chromatogram is 





CHAPTER 5 – DISCUSSION 
 
5.1 Overview of reported ZIKV genetic determinants of pathogenesis 
 How ZIKV changed from a seemingly mild virus to a human pathogen 
capable of causing severe clinical manifestations remains unclear. Since the 
emergence of ZIKV into the Western Hemisphere there has been a surge in ZIKV 
related research to elucidate the cause of the unexpected clinical manifestations, 
including Guillain-Barré syndrome and congenital Zika syndrome (2, 34, 39, 40).  The 
2015-2016 ZIKV outbreak in Brazil was orders of magnitude larger than prior outbreaks, 
and large outbreaks allow us to observe rare outcomes. It is likely that at least some of 
the new disease phenotypes are due to the size of the outbreak and extensive 
surveillance, however it may not explain everything. Phylogenetic analyses of ZIKV 
isolates from past and recent outbreaks have revealed amino acid differences between 
historic African-lineage strains and the contemporary Asian-lineage strains that are 
currently circulating in the Western Hemisphere (41, 155, 179). Several of these amino 
acid differences have been implicated in transmission, immune suppression, and 
enhanced disease.  
A single amino acid substitution in prM (S139N) has been shown to increase 
ZIKV replication in human neural progenitor cells (NPCs) and may contribute to a more 
severe microcephalic phenotype in mice (159). This residue is exposed on the surface 
of the immature virion and homology modelling from the crystal structure of the DENV 
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pr peptide showed that the 139 residue is located within a loop region that connects two 
β-strands (127). In neonatal mouse models, the contemporary Asian strains, with N139, 
were substantially more virulent than the 2010 Cambodian FSS13035 strain, which has 
S139 (159). Direct injection of the viruses into the lateral ventricle of embryonic mouse 
brains led to microcephaly for both the Asian and the contemporary American strains; 
however, the contemporary strains caused a more severe microcephalic phenotype 
than the Cambodian strain. In a reverse genetics experiments, the single amino acid 
substitution of S139N was also shown to increase the neurovirulence of the Cambodian 
strain, whereas the N139S reciprocal mutant on the contemporary GZ01 strain, isolated 
in 2016 from a patient in Venezuela (231),  had decreased neurovirulence in neonatal 
mice compared with the parental strain (159). Consistent with these findings, the S139N 
mutant virus also showed increased replication in embryonic mouse brains and 
enhanced tropism for mouse and human NPCs (159). This report suggested that the 
S139N substitution does not function as the sole contributor to microcephaly, but it may 
increase ZIKV capability to cause a severe microcephalic phenotype. However, others 
found that this mutation is not essential for fetal pathology in a mouse transplacental 
transmission model (180). Thus, we should be critical of such pronouncements that a 
single mutation is the sole cause for the microcephalic phenotype, as it can cause harm 
to public health. For example, health authorities in India advised their community not to 
worry about a 2016-2017 ZIKV outbreak after sequencing revealed the ZIKV strain 
circulating did not have the S139N substitution (154).  
 A second genetic change implicated in ZIKV pathogenesis is an A188V amino 
acid substitution located at the dimer interface of the NS1 protein (127, 157). The 
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secretion of the NS1 protein into the host circulatory system has been shown to be 
required for the efficient infection of mosquitoes when they feed on the infected host 
(232). Compared with the parental Cambodian FSS13025 strain, the A188V mutant led 
to the secretion of more NS1 and increased virus transmission from mice to mosquitoes 
in both a mouse–mosquito acquisition model and a mosquito– mouse–mosquito 
transmission model (157). The mechanism by which the A188V mutation increases NS1 
secretion remains unclear. However, the presence of A188V in NS1 led to reduced 
phosphorylation of TBK1 and the subsequent inhibition of the production of interferon-β 
(IFN-β) (158), which may facilitate viral replication.  
 Genetic changes could also have downstream effects on post-translational 
modifications, such as protein glycosylation.  Contemporary Asian-lineage strains 
possess an intact E glycosylation motif at amino acid N154. In contrast, many historic 
African-lineage ZIKV strains lack this motif (29, 174), though limited sampling of African 
ZIKV strains precludes robust conclusions about how common non-glycosylated viruses 
are in nature. E glycosylation plays a role in attachment and infectivity for DENV (83), 
WNV (67, 81, 96), and JEV (84) and has been associated with enhanced mosquito 
transmission and/or increased virulence and neuroinvasion in vertebrates for other 
flaviviruses (82, 95, 105, 107, 114, 116–118, 161, 162). ZIKV strain MR766 lacking E 
glycosylation due to a 4 amino acid deletion or a N154A substitution produced lower 
viral loads in serum and brains of A129 mice compared to glycosylated virus (98). 
Similarly, a Cambodian ZIKV strain lacking E glycosylation due to a N154Q substitution 
also resulted in decreased viral loads in serum of A129 mice compared to the WT 
glycosylated virus (99).  
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 In addition to genetic changes between historic and contemporary ZIKV 
strains, there are reported virulence differences between closely related contemporary 
strains, as well as effects of variants within a single stain on virulence in mice.  Many 
different ZIKV strains have been isolated during the recent outbreaks and distributed to 
research labs around the world (e.g. ~12 contemporary strains available from BEI 
resources). All contemporary ZIKV strains share high nucleotide identity and minimal 
amino acid differences throughout their genomes and thus have been used largely 
interchangeably to draw conclusions about the pathogenesis of contemporary ZIKV 
strains. However, not all contemporary ZIKV strains share the same pathogenic outcome 
in mice. A ZIKV strain isolated in 2013 from French Polynesia (H/PF/2013) and a strain 
isolated in 2015 from Brazil (Paraiba_01/2015) both have been shown to cause 100% 
lethality in Ifnar1-/- mice (134, 135). In contrast, a ZIKV strain isolated in 2010 from 
Cambodia (FSS13025) was only 20-30% lethal in Stat2-/- or Ifnar1-/- mice, and a strain 
isolated in 2015 from Puerto Rico (PRVABC59) was not lethal in either mouse model 
(136). However, the H/PF/2013, Paraiba_01/2015, FSS13025, and PRVABC59 strains 
were uniformly lethal in Ifnar1-/- Ifngr1-/- DKO mice (137–140). These data indicate ZIKV 
strain-specific contributions to virulence in mice, and highlight that differences in 
pathogenesis may not be evident in highly susceptible models, such as Ifnar1-/- Ifngr1-/- 
DKO mice. Strain characteristics such as virus source (human versus mosquito), disease 
outcome, geographic origin, or year of isolation, do not obviously correlate with 
pathogenic phenotype in mice, though such relationships might be revealed by comparing 
a larger number of strains under identical experimental conditions (136, 166, 216).  
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Two variants, V330L in the E protein and W98G in the NS1 protein, were identified 
in ZIKV PRVABC59 strain that affected virulence in mice. The V330L substitution 
attenuated the virus in Ifnar1-/- Ifngr1-/- DKO mice, increasing the mean time to death, and 
the addition of the NS1 W98G substitution further attenuated the virus, highlighting the 
ability of this variant to act epistatically to modulate virulence. 
Another variant in a different protein of another ZIKV strain has been reported to 
confer differential lethality in mice (233). Paraiba_01/2015, isolated from a patient serum 
sample in 2015, and a ZIKV strain isolated from a fetal brain in Rio Grande do Norte Natal 
(RGN) in 2015, showed differential lethality in Ifnar1-/- mice. Deep sequencing revealed a 
variant (A177V) in the NS2A protein of Paraiba_01/2015 that conferred lethality in Ifnar1-
/- mice. They further showed that the A177V substitution reduced host innate immune 
responses and viral-induced apoptosis in vitro.   
These reports highlight the ability of small genetic changes between different 
viruses, as well as variants within a single virus strain, to have significant phenotypic 
effects on viral replication and pathogenesis.  
5.2 My contributions to investigating the role of E glycosylation in ZIKV 
pathogenesis 
To further understand the role of ZIKV E protein glycosylation in tissue tropism 
and pathogenesis, I measured viral replication in vitro and in vivo, as well as studied 
viral attachment and infectivity, using glycosylated and non-glycosylated ZIKV from both 
African and Asian lineage strains. I used a reverse genetics platform to generate novel 
ZIKV mutants to better understand how E protein glycosylation facilitates infectivity and 
pathogenesis. My results indicated that both Asian and African lineage ZIKV strains 
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lacking E glycosylation sustained lower serum and tissue viral loads compared to WT 
virus. These results are consistent with other reports of a role for E glycosylation in 
mediating ZIKV virulence (98, 99). Notably, even though I found that ZIKV lacking E 
glycosylation resulted in lower viral loads in the serum, eyes, and brains compared to 
glycosylated virus, I observed similar viral loads in the spleen and testes, consistent 
with a previous report that glycosylated and non-glycosylated ZIKV strain MR766 
sustained similar viral loads in the spleen and liver (98), suggesting these tissues harbor 
cell types that can be targeted by the virus regardless of E glycosylation status. 
Furthermore, my observation that the ZIKV H/PF/2013 N154Q mutation was maintained 
upon intracranial inoculation, but selected against after subcutaneous inoculation, 
suggests that glycosylation provides a selective advantage to ZIKV in peripheral tissues 
but not within the brain.   
 E glycosylation likely facilitates attachment to and infection of lectin-
expressing cells, including CD14+ monocytes that are targets of ZIKV in humans (182–
185). DC-SIGN and DC-SIGNR are among several attachment factors described for 
flaviviruses such as DENV (83, 177, 186), JEV (82, 84), and WNV (67, 81, 96) as well 
as for ZIKV (85, 187, 188), though it is less clear which lectins or other attachment 
factors actually mediate ZIKV infection in mice or humans (189–191). Though mice do 
not have clear DC-SIGN or DC-SIGNR orthologs, they have eight DC-SIGN homologs 
clustered within the same genomic region (182). I found that E glycosylation facilitates 
infectivity of lectin expressing cells. However, unexpectedly, I found DC-SIGNR was 
able to augment infection by the N154Q mutant even in the absence of E glycosylation, 
whereas the T156I mutant showed little to no infectivity in DC-SIGNR-expressing cells. 
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The different infection efficiencies of the two non-glycosylated mutants on Raji DC-
SIGNR cells could result from less efficient maturation of N154Q virions compared to 
T156I virions; in this case, glycosylated prM on immature N154Q virions may partially 
complement the loss of E glycosylation (188). Alternatively, the difference in infection 
efficiencies in DC-SIGNR cells could indicate a specific role for Gln 154 or Thr 156 
independent of glycosylation, perhaps through modulation of the glycan loop and 
resulting effects on attachment and fusion (188, 191). Different amino acid substitutions 
at E154/156 of WNV conferred distinct avian host and vector competence phenotypes 
independent of E-protein glycosylation status (101). 
 I also showed that the location of the glycosylation on ZIKV E is important for 
viral replication in cell culture and in mice. A single N67 (D67N/N154Q) or double 
N67/N154 (D67N) glycosylated ZIKV were attenuated in Vero and A549 cells. ZIKV 
D67N also was attenuated in C6/36 cells, however the D67N/N154Q virus replicated 
equivalently to WT in C6/36 cells. In mice, both the D67N/N154Q and D67N viruses 
were attenuated, replicating to lower levels than the N154Q, non-glycosylated virus. 
These data may suggest that the location per se of the glycosylation on E is important, 
or distinct glycans may be added at the different positions, which in turn could influence 
attachment and infectivity. The distinct glycosylation patterns also may impact the 
antibody repertoire produced in response to infection.  
 Overall, my findings have contributed to our understanding of the role of E 
glycosylation in ZIKV pathogenesis. My work demonstrates a role for E glycosylation in 
ZIKV pathogenesis, possibly by facilitating attachment and infection of lectin-expressing 
leukocytes, and shows that the location of ZIKV E glycosylation, specifically at position 
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N154, is important for replication in certain cell types in tissue culture and for replication 
in mice.  
5.3 My contributions to elucidating ZIKV strain genetic determinants of virulence 
in mice 
To investigate differences in ZIKV viral strain virulence, I used a reverse genetics 
platform to systematically generate novel ZIKV mutants and chimeric viruses of two 
closely related ZIKV strains (H/PF/2013 and PRVABC59).  I identified and described two 
distinct genetic determinants of ZIKV strain-specific virulence; notably, both phenotypes 
were evident in Ifnar1-/- mice but masked in Ifnar1-/- Ifngr1-/- DKO mice.  
ZIKV replicates poorly in mice with intact IFN-αβ signaling, due to an inability to 
antagonize murine STAT2 and STING (131, 132, 217, 218). Thus, mouse pathogenesis 
studies typically use mice deficient in IFN-αβ signaling and both Ifnar1-/- and Ifnar1-/- 
Ifngr1-/- DKO mice are widely used in the field (137, 139, 166, 219–221). However, Ifnar1-
/- Ifngr1-/- DKO mice develop more severe disease and succumb more rapidly to ZIKV 
infection, independent of the inoculation route, compared to Ifnar1-/- mice (139, 222).  
I identified a variant (V330L) in the PRVABC59 virus stock that was not present in 
any of the other ZIKV strains we had in lab (Table 3.1). I found that the Val to Leu 
substitution in E was sufficient to attenuate on the PRVABC59 genetic backbone (10% 
lethality with PRVABC59 L330, compared to 100% lethality with PRVABC59 V330 in 
Ifnar1-/- mice), but this same substitution had no effect on the H/PF/2013 backbone (the 
L330 virus remained 100% lethal). The mechanism by which a Val to Leu substitution in 
domain III of the envelope protein would attenuate virulence, and why this would be 
specific to the PRVABC59 strain remains unclear. Apart from V330L variation, the 
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PRVABC59 and H/PF/2013 strains have identical E protein amino acid sequences, so 
the L330 substitution would be expected to have a similar effect on both strains. An 
alternative explanation is that the distinct virulence phenotypes are determined not by the 
V330L change in the E protein, but by the effect of the G1965T nucleotide change on 
RNA structure or other RNA functions. Unfortunately, the codons in this position preclude 
generating mutants that would distinguish the effects of nucleotide and amino acid 
changes at this site. Though I was able to generate a compensatory mutant that was 
predicted to restore the RNA structure of the attenuated L330 virus to that of the virulent 
V330 virus, while maintaining the Leu at position 330, this compensatory mutation did not 
restore virulence. However, these results do not exclude a role for RNA structure in the 
differential lethality of the V330 and L330 viruses, as the RNA structure prediction 
software may not be accurate, and/or we cannot exclude that the Ala to Pro change 
independently attenuates the compensatory mutant.  
Since the L330 substitution was not attenuating on the H/PF/2013 background, 
and the other three amino acids that differ between the two strains did not have an effect 
on virulence, I sought to identify which of the other 31 nucleotide differences between the 
two strains were responsible for the differential lethality. Using chimeric viruses, I was 
able to narrow down the virulence determinant to 6 nucleotide differences in the 3’ region 
of the H/PF/2013 genome (including NS5 and the 3’UTR), though the mechanism by 
which these nucleotide changes modulate virulence remains unclear. Possible 
mechanisms could include effects on RNA structure and/or post-transcriptional 
modifications, though these changes did not obviously disrupt predicted RNA structures 
or predicted m6A modification sites. And though the one nucleotide difference that falls 6 
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nucleotides upstream of the first stem loop structure in the 3’ UTR was not solely able to 
confer lethality, it is plausible that one or more of the other nucleotide changes between 
PRVABC59 and H/PF/2013 could impact the production, stability, or function of 
subgenomic flavivirus RNA (sfRNA). sfRNA is a stable RNA degradation product resulting 
from stalling of the cellular 5’–3’-exoribonuclease Xrn1 on RNA structures in the flavivirus 
3’ UTR, which has been shown to modulate replication and virulence of ZIKV and other 
flaviviruses (227, 230, 234–236).  
Altogether, my work identifies a large and previously unreported difference in 
virulence between two commonly used ZIKV strains, in two widely used mouse models 
of ZIKV pathogenesis (Ifnar1-/- and Ifnar1-/- Ifngr1-/- DKO mice). My data further describe 
the effect of a previously reported variant in the PRVABC59 strain that appears to be 
attenuating only on the PRVABC59 genetic background. I also identified a novel role for 
non-coding changes as ZIKV virulence determinants, suggesting possible effects on RNA 
structure or post-transcriptional modifications. My results highlight that even very closely 
related virus strains can produce significantly different pathogenic phenotypes in common 
laboratory models.  
5.4 My contributions to evaluating the effect of xrRNA stability on ZIKV replication 
 To test  whether mutations that destabilize xrRNA1 or xrRNA2 affect replication, I 
used PCR site-directed mutagenesis to introduce mutations predicted to destabilize 
xrRNA1 or xrRNA2 in a previously described infectious clone of the Asian-lineage ZIKV 
strain H/PF/2013 (164). I found that mutations in xrRNA1 or xrRNA2 do not significantly 
affect the production of infectious virus particles into the supernatants, but may cause a 
slight replication defect as seen by a significantly smaller foci by FFA. However, 
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competition assays revealed no detectible replication advantage of WT virus over 
xrRNA1 or xrRNA2 mutants, though a destabilized xrRNA1 mutant replicated better 
than an xrRNA2 mutant. The inability to recover double mutant virus with mutations in 
both xrRNA1 and xrRNA2 suggests these structures are essential for ZIKV replication. 
Overall, my data suggests xrRNA activity is essential for ZIKV replication but xrRNA1 
and xrRNA2 are largely redundant.  
5.5 Future directions for the flavivirus field 
 Results presented in this dissertation have contributed to expanding our 
knowledge of genetic determinants of ZIKV pathogenesis. Along with concurrent work 
defining other genetic determinants of ZIKV infection, replication, and pathogenesis in 
related strains, as well as other flaviviruses, we are continually learning more about 
flavivirus biology and the molecular determinants that impact pathogenesis.  
 Despite all the progress we have made towards unraveling which aspects of the 
viral genome are important, and how genetic changes may lead to more pathogenic 
viruses, we still have much to learn. Understanding how ZIKV is able to spread through 
sexual transmission, cause neurological disease and congenital Zika syndrome are not 
fully understood. Elucidating further how the location of E glycosylation can impact what 
kind of glycan is added, from different cell types, and how that glycan impacts the next 
round of replication will further our understanding of ZIKV biology. Also understanding 
how distinct glycans on E can impact the antibody repertoire elicited in response to 
infection, especially in DENV endemic regions where most individuals have existing 
antibodies to DENV that may cross react with ZIKV, is of great importance. Unraveling 
which viral genetic changes may have epistatic effects or impact long range RNA- RNA 
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interactions that affect viral replication and pathogenies requires more research. Further 
studies to understand the extent to which ZIKV sfRNA interact with host and vector 
proteins to modulate infection and replications are required. Continuous fundamental 
research of both the viruses and the hosts will elucidate these complex relationships 
between flaviviruses and the hosts they infect. Uncovering the answers to these 
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